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ABSTRACT 
 
 
The immune system utilizes many regulatory mechanisms to limit immune 
responses and ensure that immune cells target foreign pathogens and not healthy cells of 
the body. However, some immune cells can escape these checkpoints and attack the 
body’s healthy cells, leading to tissue destruction and devastating autoimmune disorders. 
For example, multiple sclerosis (MS) occurs when immune cells attack the myelin sheath 
surrounding neurons of the central nervous system (CNS). Likewise, the destruction of 
pancreatic islet cells by dysregulated immune cells leads to type 1 diabetes (T1D). 
Remarkably, there are more than 80 types of autoimmune diseases. An estimated 50 
million Americans suffer from autoimmune disease, and the prevalence continues to 
increase. These diseases are chronic and potentially life threatening, with associated 
healthcare costs estimated at $100 billion annually. Current therapies to limit 
autoimmune diseases often include immunosuppressant medications that also increase 
susceptibility to infections and tumors. Therefore, therapeutic treatments which 
specifically inhibit autoreactive immune cells, while sparing immune cells required for 
pathogen or tumor clearance would significantly improve treatment options.     
 
Drak2, a serine-threonine kinase, expressed abundantly in T and B cells, is a 
negative regulator of T cell activation. However, unlike other negative regulators, Drak2 
plays an important role in eliciting autoimmunity, rather than preventing it. This is 
demonstrated by the finding that Drak2-/- mice are resistant to autoimmune disease in 
mouse models of T1D and MS. This resistance is due to reduced accumulation of Drak2-/- 
autoreactive T cells in the pancreas and CNS compared to wildtype mice. The decreased 
accumulation of autoreactive T cells in the target organs of Drak2-/- mice is partly due to 
diminished survival. Interestingly, despite Drak2-/- T cells being more sensitive to death, 
pathogen clearance and tumor surveillance are maintained in Drak2-/- mice. Therefore, 
inhibiting Drak2 is a potential alternative therapeutic approach to inhibit autoreactive T 
cells without suppressing the entire immune system. Thus, there is major interest in 
identifying the mechanisms by which Drak2 inhibits autoimmunity. This dissertation 
discusses the current knowledge of Drak2, its role in autoimmunity, and its potential as 
an inhibitory target to treat disease.  
 
We utilized several in vivo T cell adoptive transfer models to show that resistance 
to T1D was due to the absence of Drak2 in T cells rather than pancreatic β-cells, and that 
regulatory T cells (Tregs) were required to elicit resistance. Further analysis revealed that 
in the absence of Drak2, IL-2 signaling and Treg development increased and likely 
contributes to disease resistance. We also determined that Drak2 is not a negative 
regulator of TGF-β signaling in primary T cells, opposing a previous report. Thus it is 
unlikely that alterations in the TGF-β signaling pathway mediate autoimmune disease 
resistance in the absence of Drak2. Finally, to advance our understanding of how Drak2 
contributes to T cell accumulation, and ultimately to T1D and MS, we established in vitro 
culture methods to recapitulate the survival defect observed in the absence of Drak2 in 
vivo. Interestingly, we discovered that Drak2 modifies the actin polymerization pathway 
either directly or indirectly, and that Drak2-/- T cells exhibited defects in cell cycle 
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progression, proliferation, and other actin-mediated T cell functions that impair T cell 
accumulation. Together, these data highlight novel insights into the roles of Drak2 in T 
cell function and autoimmunity, and suggest that subtle changes within these diverse 
processes may cooperate to contribute to autoimmune disease resistance in the absence of 
Drak2. 
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CHAPTER 1.    INTRODUCTION 
 
 
Drak2 
 
T cells play crucial roles in tumor surveillance and protection against invading 
pathogens. However, if not properly regulated, T cells can attack normal, healthy cells of 
the body. This unregulated response may lead to tissue and organ destruction and 
devastating autoimmune diseases such as type 1 diabetes (T1D) and multiple sclerosis 
(MS). The immune system utilizes several mechanisms to regulate T cells, reduce 
damage, and prevent autoimmunity. One important regulatory mechanism is preventing 
inappropriate T cell activation. Several signaling molecules, including Cbl and PTEN, 
can negatively regulate inappropriate T cell activation. Removing these molecules 
increases susceptibility to autoimmunity [1–3], highlighting the importance of  regulating 
T cell activation.  
 
 DAP kinase-related apoptosis-inducing protein kinase 2 (Drak2) is also a negative 
regulator of T cell activation [4–6]. Drak2 was originally cloned due to its homology to 
the kinase domain of Death-associated protein kinase (DAPK) [7]. While the kinase 
domain of Drak2 is homologous with the other DAPK kinase family members (DAPK, 
DRP-1, ZIPK, and Drak1), its non-catalytic C-terminal region is structurally distinct [7]. 
These serine-threonine kinase proteins are characterized as pro-apoptotic proteins based 
on their ability to induce apoptosis upon overexpression in cell lines [8]. However, 
several studies highlighted additional roles for Drak2 beyond the scope of apoptosis, and 
in particular, its role in T cells and autoimmunity is of considerable interest as a potential 
target to treat autoimmune diseases.  
 
 
Expression 
 
Drak2 is expressed most abundantly in lymphoid organs, although expression was 
also detected in various tissues during embryogenesis, in some tumor types, and in 
pancreatic β-islet cells after stimulation [4,5,9–14]. Within the lymphoid compartment, 
Drak2 expression increases during T and B cell development, and remains abundant in 
mature T and B cells. On the other hand, Drak2 is expressed at extremely low levels in 
natural killer cells, and is not expressed in macrophages and dendritic cells. 
 
Interestingly, the intracellular localization of Drak2 varies depending upon cell 
type and activation state. Drak2 was primarily restricted to the cytoplasm upon ectopic 
expression in ACL-15, HeLa, and WI-38 cells [15,16]. Alternatively, its overexpression 
in NRK, NIH 3T3, and Caco-2 cells caused Drak2 to localize to the nucleus. In T cells, 
Drak2 localizes to both the cytoplasm and the nucleus [4]. However, shortly after 
stimulation, Drak2 expression decreases in the nucleus, but is retained in the cytoplasm 
for 24 hours before total expression levels decrease due to reduced mRNA transcription, 
suggesting that T cell receptor (TCR) stimulation mediates Drak2 localization and 
expression.   
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Drak2 activation and protein interactions 
 
In addition to altering the localization and expression of Drak2, TCR stimulation 
also induces Drak2 phosphorylation [6]. The release of intracellular calcium stores with 
thapsigargin also activates Drak2. Three kinases have been implicated in Drak2 
phosphorylation. First, Drak2 autophosphorylates itself, which is dependent on the 
presence of calcium [6]. Second, Drak2 was phosphorylated by PKC-γ, a serine-threonine 
kinase that is activated by calcium [16]. Finally, Protein kinase D (PKD), a protein 
belonging to the same calcium/calmodulin-dependent superfamily of serine-threonine 
kinases as Drak2, phosphorylated Drak2 in an in vitro kinase assay [17]. PKD catalytic 
activity also promoted Drak2 autophosphorylation in 293T cells and Jurkat cells. In cells 
ectopically expressing Drak2, PKD and Drak2 interacted at the mitochondria membrane, 
and this interaction was enhanced upon thapsigargin treatment. Thus, Drak2 function and 
activation is associated with intracellular calcium release. 
 
The kinase activity of Drak2 requires both the ATP-binding loop within its kinase 
domain and the C-terminal region, which contains a functional nuclear localization signal 
(NLS) sequence [6]. In vitro kinase assays revealed that, in addition to phosphorylating 
itself, Drak2 phosphorylates myosin light chain as an exogenous substrate [7,9]. Drak2 
also phosphorylated p70S6 kinase, which plays important roles in protein synthesis and 
cell cycle progression [14]. Drak2 overexpression in NIT-1 cells increased p70S6 kinase 
phosphorylation, while siRNA-mediated knockdown of Drak2 resulted in reduced p70S6 
kinase phosphorylation.   
 
In addition to its substrates, Drak2 also interacts with other proteins. When Drak2 
was overexpressed in COS-7 cells, it interacted with the calcium-binding protein, 
calcineurin homologous protein (CHP). This interaction was calcium-dependent, and 
caused inhibition of Drak2 kinase activity [9,18]. Drak2 was also shown to interact with 
the transforming growth factor-β (TGF-β) receptor I in several tumor cell lines. Drak2 
inhibited TGF-β signaling in these cells by blocking phosphorylation of the Smad2/3 
complex [10]. These potential substrates and interacting proteins were identified mainly 
through in vitro kinase assays or overexpression in cell lines, therefore it is not known 
what Drak2 may phosphorylate in vivo at physiological levels of expression.   
 
 
Function 
 
Other members of the DAPK kinase family (DAPK, DRP-1, and ZIPK) have 
well-established roles as pro-apoptotic proteins [8]. However, the role of Drak2 in 
apoptosis-mediated cell death is less clear. Early studies utilizing NIH 3T3 cells 
demonstrated that ectopic expression of Drak2 induced apoptosis, which required Drak2 
kinase activity [7,9]. However, enforced expression of Drak2 did not cause apoptosis in 
COS-7 cells [7]. Additional investigations suggest that the intracellular location of Drak2 
determines whether it contributes to apoptosis [15]. Ectopic Drak2 expression in ACL-
15, HeLa, and WI-38 cells, where Drak2 was localized to the cytoplasm, did not enhance 
cell death. Alternatively, overexpression of Drak2 in NRK, NIH3T3, and Caco-2 cells led 
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to Drak2 localization to the nucleus and induced apoptosis. Interestingly, UV irradiation 
of ACL-15 cells, which exhibit cytoplasmic Drak2 expression, resulted in nuclear 
translocation of Drak2 and subsequent apoptosis. Thus, Drak2 localization to the nucleus 
correlates with increased cell death in overexpression experiments.  
 
In addition to cell lines, the potential apoptotic effects of Drak2 have been studied 
in pancreatic β-islet cells. Drak2 augmented free fatty acid (FFA)-mediated apoptosis in 
vitro in primary β-islet cells and NIT-1 insulinoma cells [13]. Furthermore, transgenic 
overexpression of Drak2 via the β-actin promoter increased apoptosis in islet cells 
following FFA stimulation [14]. Drak2 overexpression in these models mediated 
apoptosis via reduced induction of the anti-apoptotic family members Bcl-2, Bcl-xL, and 
Flip.  
 
The role of Drak2 in T cell apoptosis has also been extensively studied. 
Transgenic expression of Drak2, via the β-actin promoter, increased apoptosis in T cells 
following anti-CD3 and anti-CD28 stimulation, but only in the presence of exogenous IL-
2 [12]. This increased apoptosis correlated with upregulation of pro-apoptotic proteins. 
However, ectopic expression of Drak2 in primary T cells did not increase apoptosis upon 
anti-CD3 and anti-CD28 stimulation even in the presence of IL-2 [6]. Furthermore, the 
absence of Drak2 did not cause a reduction in apoptosis in primary T cells upon in vitro 
stimulation with anti-CD3 and anti-CD28, or during an in vivo infection with 
lymphocytic choriomeningitis virus (LCMV) [4,5]. Moreover, thymocytes from Drak2-/- 
mice did not exhibit impaired apoptosis during negative selection or upon stimulation 
with multiple agents, including anti-CD3, anti-Fas, peptide-pulsed antigen-presenting 
cells, and γ-irradiation compared to wildtype thymocytes [4]. Collectively, these data 
indicate that Drak2 does not play a required pro-apoptotic role in primary T cells. It is 
possible that the role of Drak2 varies between cell types. In addition, overexpression of 
Drak2 in cell lines that do not normally express Drak2, and enhanced ectopic expression 
in primary cells may impact cell survival due to inappropriate expression levels of Drak2. 
Thus, overexpression experiments do not necessarily indicate how Drak2 functions 
during normal physiological processes. The fact that Drak2-/- mice develop normally, and 
apoptosis of T cells from these mice is comparable to wildtype mice, suggests that Drak2 
is not required for apoptosis.  
 
Contrary to decreased cell death that would be expected in Drak2-/- T cells if 
Drak2 was required for apoptosis, Drak2-/- T cells were actually more susceptible to 
apoptosis upon in vitro and in vivo stimulation. In vitro superantigen staphylococcal 
enterotoxin B (SEB) stimulation enhanced death of Drak2-/- T cells compared to wildtype 
T cells [19]. This enhanced death was associated with reduced anti-apoptotic protein 
expression, and retroviral overexpression of the anti-apoptotic protein Bcl-xL rescued 
this survival defect. Reduced survival of Drak2-/- T cells also contributed to an impaired 
antibody response following immunization with NP16-CGG [20]. Drak2-/- mice exhibited 
reduced development of germinal centers (GC), which was associated with decreased 
numbers of GC B cells, and lower levels of antibodies, compared to wildtype mice 
following immunization. Interestingly, induced expression of the anti-apoptotic protein 
Bcl-xL in T cells rescued these B cell defects, suggesting that the impaired B cell 
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response was due to decreased T cell survival in the absence of Drak2. Furthermore, in 
an allogeneic tumor model, Drak2-/- T cells exhibited increased cell death following 
allogeneic activation, which culminated in decreased allogeneic rejection [21]. Taken 
together, these data suggest that following stimulation, T cells are more susceptible to 
death in the absence of Drak2, and therefore Drak2 plays a critical role in promoting T 
cell survival rather than apoptosis. 
 
While Drak2 was not critical to induce apoptosis of T cells, and therefore does not 
appear to function as a pro-apoptotic protein, several studies suggest that Drak2 functions 
as a negative regulator of TCR signaling. Peripheral Drak2-/- T cells were 
hyperproliferative, exhibited enhanced cytokine production, and increased calcium flux 
in response to suboptimal TCR stimulation [4]. Likewise, Drak2-/- CD4+ thymocytes 
exhibited increased calcium flux compared to wildtype thymocytes in response to anti-
CD3 and anti-CD4 stimulation [5]. In addition, ectopic expression of Drak2 via the lck 
proximal promoter led to high levels of Drak2 expression in double positive thymocytes 
and diminished calcium flux [22]. Interestingly, Drak2 autophosphorylation requires 
calcium mobilization, and in the absence of Drak2, TCR-induced calcium flux is 
increased [6]. This suggests that Drak2 is activated in response to calcium, and then 
functions to negatively regulate calcium signaling. In addition, thapsigargin treatment 
enhanced Drak2 expression in splenic T and B cells, and Drak2 potentially interacts with 
proteins involved in calcium signaling (PKC-γ, CHP, and PKD). Together, these studies 
demonstrate that Drak2 modulates calcium signaling, which may mediate its negative 
regulatory role during T cell activation. Thus, in the absence of Drak2, the TCR 
activation threshold is reduced, and Drak2-/- T cells are hypersensitive to suboptimal 
stimulation.   
 
 
Drak2 and Autoimmunity 
 
Because Drak2-/- mice have hypersensitive T cells, it was reasonable to 
hypothesize that these mice would be more susceptible to autoimmune diseases. 
Surprisingly, Drak2-/- mice do not develop spontaneous autoimmune disease. In fact, in 
an induced model of autoimmune disease, experimental autoimmune encephalomyelitis 
(EAE), Drak2-/- mice are paradoxically more resistant to disease [4,23]. Drak2-/- mice 
exhibited reduced incidence, severity, and numbers of infiltrating T cells in the CNS 
compared to wildtype mice. Furthermore, disease resistance was intrinsic to the T cells, 
and due, at least in part, to enhanced death of the autoreactive T cells. This is supported 
by the fact that enforced expression of Bcl-xL in T cells restored EAE susceptibility in 
Drak2-/- mice, suggesting that Drak2 promotes survival of autoreactive T cells, which 
contributes to autoimmune disease in this model [19]. In addition, Drak2-/- mice are 
resistant to disease in the Non-obese diabetic (NOD) mouse model of T1D. Similarly, this 
disease resistance is due to decreased accumulation of T cells in the pancreatic islets, 
possibly due to enhanced apoptosis of T cells in the absence of Drak2 [23]. These data 
indicate that Drak2 expression in T cells promotes the survival of autoreactive T cells and 
contributes to autoimmunity. In support of this, transgenic mice ectopically expressing 
Drak2 via the T cell specific lck promoter exhibited enhanced incidence of spontaneous 
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autoimmunity compared to wildtype littermate controls [22]. Furthermore, the onset and 
mean clinical severity of EAE in Drak2 transgenic mice was enhanced compared to 
wildtype mice. This enhanced autoimmunity was due to activation of autoreactive T cells 
that either escaped thymic negative selection or exhibited lower activation thresholds, due 
to overexpression of Drak2. Together, these data indicate that Drak2 expression in T 
cells contributes to autoimmunity. 
 
However, Drak2-/- mice were not resistant to disease in all models of 
autoimmunity [23]. Specifically, Drak2-/- mice responded similar to wildtype mice in 
models of autoimmunity in which disease is mediated by autoantibodies or cells of the 
innate immune system, such as a collagen-induced model of arthritis, systemic lupus 
erythematosus (SLE), and passive cutaneous anaphalaxis. These data support the notion 
that Drak2 plays a role specifically in T cell-mediated autoimmune diseases. 
 
While the role of Drak2 in the EAE model was intrinsic to the T cells, and due to 
increased susceptibility to apoptosis of autoreactive cells, other data suggest that Drak2 
may contribute to T1D by affecting survival of pancreatic β cells [14]. Treatment of islet 
cells with inflammatory cytokines led to the upregulation of Drak2 expression in these 
cells, which correlated with islet apoptosis. In addition, overexpression of Drak2 (driven 
by the β-actin promoter) in transplanted islets enhanced apoptosis and was accompanied 
by increased disease incidence in the streptozotocin-induced model of T1D. According to 
this view, NOD.Drak2-/- mice could be resistant to T1D due to the absence of Drak2 in β-
islet cells, which would enhance islet survival during disease. However, ectopic 
expression of Drak2 in islet cells may not mimic physiological Drak2 expression and/or 
function. Therefore, identifying the cell type(s) in which Drak2 elicits its effects is 
important to study its mechanism of action. It remains unclear if the absence of Drak2 in 
T cells, β-islet cells, or a combination of both, mediates resistance to T1D.  This 
dissertation will address and clarify this question.  
 
 
Drak2 and Infectious Diseases 
 
Given that Drak2-/- T cells are more susceptible to apoptosis upon stimulation and 
that this susceptibility contributes to resistance to autoimmune disease, this survival 
defect could also affect immunity to infectious pathogens. Surprisingly, Drak2-/- mice 
responded comparably to wildtype mice following a variety of infections. During 
lymphocytic choriomeningtitis virus (LCMV) infection, wildtype and Drak2-/- mice had 
similar numbers of antigen-specific T cells and viral clearance was enhanced in the 
absence of Drak2 [4] and (unpublished data). Furthermore, Drak2-/- T cells were able to 
infiltrate nonlymphoid organs following LCMV infection, although they were more 
susceptible to death in the brain during later stages of infection [4,23]. These data suggest 
that the absence of Drak2 does not impair the immune response to LCMV. 
 
In addition, Drak2-/- mice exhibited a greater survival rate than wildtype mice in 
response to West Nile Virus (WNV)-induced encephalitis (47% vs. 16.7%, respectively) 
[24]. Although viral loads and kinetics were similar in the blood and spleen, brain viral 
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load was significantly reduced in Drak2-/- mice compared to wildtype mice. WNV-
infected T cells may function to carry virus into the brain. Therefore, the reduction in 
viral load was attributed to reduced T cell infiltration in the CNS in response to WNV 
infection. Lastly, Drak2-/- mice respond similar to wildtype mice during intra-cerebral 
and intraperitoneal infection with mouse hepatitis virus in terms of T cell activation, 
expansion, and cytokine production [25,26]. Surprisingly, memory T cell function was 
enhanced in the absence of Drak2. Thus, although Drak2-/- T cells are more susceptible to 
death following stimulation, Drak2-/- mice respond effectively to these viral pathogens, 
suggesting that Drak2 expression is not required to elicit productive immune responses 
against infectious agents.  
 
Unpublished data from our lab also show that Drak2-/- mice launch effective 
immune responses to various other pathogens. Drak2-/- mice exhibited similar clearance 
and increased numbers of antigen-specific cells in response to the bacterium, Listeria 
monocytogenes, compared to wildtype mice. In addition, following influenza virus 
infection, Drak2-/- mice showed similar survival, viral clearance, and numbers of virus-
specific T cells as wildtype mice. Furthermore, Drak2-/- mice exhibit no alterations in 
response to the protozoan Leishmania major, based on the number of Leishmania-
specific T cells. Also, the number of IL-4 producing CD4 T cells responding to the 
parasite, Heligmosomoides polygyrus, was similar between wildtype and Drak2-/- mice. 
In fact, there was less shedding of the parasite in the absence of Drak2. Therefore, not 
only do Drak2-/- mice retain immune function in response to an array of pathogens, but 
they actually exhibit enhanced responses in many infection models.   
 
 
Drak2 and Tumorigenesis  
 
DAPK, the founding member of the DAPK family, functions as a tumor 
suppressor in several different types of cancer [27–29]. Therefore, studies explored 
whether Drak2 also suppresses tumorigenesis. A correlation between reduced Drak2 
expression and elevated cyclooxygenase-2 (COX-2) expression was found in human 
colorectal tumors, leading to enhanced tumor growth, suggesting that Drak2 functions as 
a tumor suppressor [30]. Moreover, enhanced expression of Drak2 induced cell death in 
colon cancer cell lines, via COX-2 inhibition, highlighting an anti-tumor role for Drak2 
via pro-apoptotic effects.  In addition, in a human acute myeloid leukemia (AML) cell 
line, knockdown of the oncogene MYB led to induction of Drak2, which served as a pro-
apoptotic protein to induce tumor cell death [11]. Furthermore, up-regulation of MYB and 
down-regulation of Drak2 was seen in AML patients, further suggesting a role for Drak2 
in tumor suppression. Alternatively, opposing evidence suggests that Drak2 functions as 
an oncogene. Drak2 was preferentially expressed in skin samples from cutaneous T-cell 
Lymphoma (CTCL) patients.  In addition, Drak2 was identified as an antigen that elicited 
antibody reactions in some of the CTCL patient sera but not in healthy patients, 
indicating a tumor-dependent antibody production and implicating Drak2 expression as a 
risk factor for this disease [31]. In addition, enhanced Drak2 expression in several tumor 
cell lines led to a decrease in TGF-β signaling, overriding the function of TGF-β in tumor 
suppression [10]. These data suggest that Drak2 may function as a negative regulator of 
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TGF-β signaling and serve as an oncogene in basal-like and HER2-enriched human 
breast tumors and cell lines, where it is highly expressed. Furthermore, loss of Drak2 
expression inhibited tumor growth in a xenograft model, implicating that Drak2 
potentiates tumor development. 
 
Due to opposing findings implicating Drak2 as either a tumor suppressor or an 
oncogene, the role of Drak2 in tumor surveillance and suppression was investigated in 
Drak2-/- mice utilizing various in vivo tumor models [32]. Drak2-/- mice did not exhibit 
altered onset, severity, or incidence of transplanted tumors, spontaneous tumors resulting 
from carcinogen treatment, tumors induced by the absence of the p53 tumor suppressor, 
or inflammation-induced tumors. These data suggest that Drak2 is neither a prerequisite 
tumor suppressor nor oncogene, and it is not required for immune-cell mediated tumor 
surveillance. Further, the role for Drak2 as an oncogene or tumor suppressor is dependent 
on the tumor type.   
 
 
Therapeutic Implications 
 
Effective treatments of autoimmune diseases require a balance between blocking 
the adverse effects of autoreactive T cells while preserving immune cell function.   
Drak2-/- mice are resistant to T1D and MS, but retain the ability to respond effectively to 
infectious pathogens and tumors. Therefore, Drak2 inhibition represents a potential 
therapeutic approach to treat autoimmune disorders such as MS and T1D without 
increasing the risks of tumor development and increased pathogen susceptibility caused 
by broad immunosuppression.  
 
Drak2 has also been implicated as a therapeutic target in West Nile Virus 
infection. During infection with WNV, pathogenesis in the CNS may be mediated by T 
cells that transport the virus to the brain [24]. Drak2-/- mice exhibited decreased T cell 
infiltration in the brain, which decreased viral load and increased survival. These findings 
suggest that Drak2 contributes to WNV disease pathogenesis, which could be reduced 
through Drak2 inhibition.   
 
In addition to T1D, Drak2 has also been implicated in type 2 diabetes (T2D) [13]. 
While reduced insulin sensitivity is the main initial concern during T2D, islet cell 
apoptosis is a long-term mediator of disease. Upon overexpression of Drak2 via the β-
actin promoter, transgenic islet cells exhibited increased apoptosis in response to free 
fatty acid treatment, a compound that is elevated in obesity and supports T2D 
development, suggesting a role for Drak2 in islets cells as a pro-apoptotic protein. Thus, 
further studies should investigate if enhanced Drak2 gene expression is a risk factor in 
pre-diabetic T2D patients, which could implicate Drak2 as a therapeutic target. 
 
Furthermore, Drak2 may also contribute to allogeneic rejection [21]. Following 
transplantation of allogeneic tissue, T cells specific for alloantigens can become activated 
and promote allograft rejection. Long-term treatments using immunosuppressant drugs 
can increase toxicity and risk of pathogenic infections. In an allogeneic tumor transplant 
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model, Drak2-/- T cells did not reject the transplanted tumors, due to enhanced cell death 
of the T cells, highlighting that inhibition of Drak2 may elicit protective effects and 
enhance patient outcome following organ transplant. 
 
Based on the aforementioned investigations, Drak2 is a compelling therapeutic 
target to inhibit for the treatment of T cell–mediated autoimmune diseases, to prevent 
graft rejection, and to inhibit growth of certain tumors in which it functions as an 
oncogene. An initial attempt to discover novel small-molecule inhibitors of Drak2 
identified a compound that exhibited inhibition of Drak2. However, this compound also 
blocked other members of the DAPK family [33], rendering it a nonselective inhibitor. 
Subsequent studies revealed a more selective compound that served as a dual inhibitor for 
only Drak1 and Drak2, however inhibitory effects were not robust [34]. Therefore, more 
work is needed to develop selective and effective functional inhibitors of Drak2 to further 
explore its potential as a therapeutic target. 
 
 
Organization of the Dissertation 
 
Although several data indicate that Drak2 plays a role in autoimmune disease, the 
precise mechanisms by which it impacts autoimmunity are not clear. Understanding the 
function of Drak2 is of great importance, as it will provide insight into novel mechanisms 
that mediate T cell dysregulation to enhance susceptibility or resistance to autoimmune 
disease. This understanding will benefit future studies to develop novel therapeutic 
treatments for these diseases. The work in this dissertation was proposed to investigate 
the function of Drak2 and mechanisms by which it contributes to autoimmune disease 
and T cell function. 
 
In chapter 3, we explored the mechanism by which Drak2 contributes to 
autoimmunity by first examining the cell type(s) in which Drak2 expression contributes 
to T1D.  Although many lines of evidence indicate that Drak2 plays a critical role within 
the T cells, other data suggested that Drak2 expression in β-islet cells augments T1D 
[14,23]. Therefore, we investigated whether Drak2 expression in T cells, β-islet cells, or 
both cell types regulated disease in the NOD model of T1D. We determined that, similar 
to the EAE model, resistance to T1D was also due to the absence of Drak2 in the T cells. 
We next showed that in the absence of Drak2, IL-2 signaling was enhanced in 
thymocytes, which led to increased proportion of cells expressing phosphorylated Stat5 
and enhanced Foxp3 induction. Furthermore, regulatory T cells (Tregs) were required for 
disease resistance and inhibition of autoreactive NOD.Drak2-/- T cells.  
 
Knowledge gained from the investigations completed in chapter 3, showing that 
Drak2 contributes to autoimmune disease via its function in T cells, coupled with a 
previous report suggesting that Drak2 is a negative regulator of TGF-β signaling [10], led 
to the research in chapter 4 to investigate the role of Drak2 in TGF-β signaling within T 
cells. The study indicating that Drak2 negatively regulates TGF-β signaling utilized a 
variety of cell lines and whole splenocytes, but did not test whether Drak2 inhibited TGF-
β signaling specifically in T cells. It was reasonable to hypothesize that enhanced TGF-β 
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signaling in the absence of Drak2 mediated autoimmune disease resistance, because the 
TGF-β pathway is critical for suppressing autoimmunity.  Therefore, we performed 
several in vitro experiments to determine if Drak2 functions as a negative regulator of 
TGF-β signaling in primary T cells. We conclude that Drak2 does not negatively regulate 
TGF-β signaling in T cells, and thus does not contribute to autoimmunity via alterations 
in TGF-β signaling.  
 
The research described in chapter 5 investigated mechanisms by which Drak2 
may alter T cell accumulation, as decreased T cell accumulation in the target organs 
during T1D and MS mediates disease resistance in the absence of Drak2. Although 
enhanced T cell apoptosis has been implicated, detailed proliferative studies had not been 
completed. To explore Drak2 function more directly, we established in vitro culture 
conditions that elicited decreased T cell accumulation in the absence of Drak2, similar to 
in vivo observations. We discovered defects in proliferation and decreased actin 
polymerization in Drak2-/- T cells compared to wildtype T cells. Efficient actin 
polymerization facilitates many T cell processes including activation, calcium signaling, 
and cell cycle progression.  Each of these processes cooperate to elicit productive T cell 
survival and proliferation, both of which lead to T cell accumulation. Our preliminary 
data and previously published investigations suggest many of these actin-mediated 
processes may be altered in Drak2-/- T cells compared to wildtype T cells. Therefore, we 
investigated actin polymerization in the absence of Drak2. In addition to a significant 
reduction in polymerized actin, we also found alterations in downstream actin-mediated T 
cell functions in the absence of Drak2, suggesting a novel role for Drak2 in directly or 
indirectly mediating actin dynamics. This dissertation sheds light on some of the debated 
questions regarding Drak2 and introduces novel insights and new roles for Drak2 in 
autoimmunity and T cell function. 
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CHAPTER 2.    MATERIALS AND METHODS 
 
 
Mice 
 
C57BL/6.Drak2-/- mice were previously described and backcrossed 19 generations 
to C57BL/6 [4]. OT-II mice were obtained from Kristin Hogquist [35] and TGF-β DNRII 
mice were obtained from Hongbo Chi [36]. C57BL/6, CD451/1, OT-I and NOD.SCID 
mice were purchased from Jackson Laboratories. NOD.Drak2-/- and  
NOD.BDC2.5.Drak2-/- mice were previously described [23]. NOD.Drak2-/- mice were 
crossed to the NOD background for greater than 11 generations. SNP analysis with 
Illumina Low Density Linkage Panels showed that greater than 99.3% of the SNPs 
analyzed in NOD.Drak2-/- mice, and 100% of the SNPs analyzed in Drak2.NOD.SCID 
mice were of NOD origin (Charles River Laboratories). Mice were age and gender 
matched within each experiment and held under specific pathogen-free conditions at St. 
Jude Children’s Research Hospital. Animal studies met the approval of the Animal Ethics 
Committee. 
 
 
Fluorescence-Activated Cell Sorting and Purification of Lymphoid Populations 
 
Mouse T cells were purified from spleen and/or lymph nodes and FACS sorting 
using antibodies specific for CD4, CD8, CD25, CD44, CD45RB, and CD62L 
(eBioscience). Naïve T cells (CD4+ or CD8+) were CD44-, CD25-CD45RBhi, CD25-
CD44lo, or CD25-CD44loCD62Lhi. Regulatory T cells were CD4+CD25+CD45RBlo 
[37,38]. Cell sorting was performed using the iCyt Reflection or SY3200 Cell Sorters 
(Sony Biotechnology).  
 
 
Magnetic Separation of T Cells 
 
Mouse T cells were purified from spleen and/or lymph nodes by negative 
selection with biotin-conjugated antibodies specific for B220, CD8 (for CD4 T cell 
enrichment only), CD11b, DX5, and MHC class II (eBioscience), followed by separation 
with streptavidin-conjugated magnetic beads (Miltenyi Biotech), and collection of the 
flow-through fraction of cells. T cell populations were greater than 95% pure. 
 
 
CFSE Labeling 
 
Following purification, cells were treated with 5,6-carboxyfluorescein 
succinimidyl ester (CFSE) (Molecular probes) as previously described [39], with 
modifications.  Cells were washed twice with PBS and incubated with CFSE prepared at 
0.4 µM in pre-warmed PBS (0.1% FCS), for 10 minutes at 37°C.  Cells were washed 
twice with RP10 advanced media (RPMI advanced media, 10% FCS, 5nM Hepes, 50 
µg/ml Pen-Strep, 4mM L-glutamine, 50 uM BME, 50 µg/ml gentamicin). 
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Flow Cytometric Analysis 
 
Single cell suspensions from in vitro cultures or organs were stained with 
antibodies specific for CD4, CD8, CD25, CD44, CD45RB, CD45.1, CD45.2, and/or 
CD62L (eBioscience and BioLegend). Cell death and viability was determined utilizing 
Annexin V (BD Biosciences) or Fixable Viability Dye (eBioscience), according to 
manufacturer’s instructions. To detect Foxp3+ cells, suspensions were stained with 
antibodies specific for CD4, CD8, and CD25. Cells were then fixed and permeabilized 
with the Foxp3/Transcription Factor Staining Buffer Set according to manufacturer’s 
instructions (eBioscience) and stained with anti-Foxp3 antibody (eBioscience). For F-
actin and G-actin analysis, cells were treated with viability dye and stained with 
antibodies specific for CD4. Cells were fixed and permeabilized with the 
Foxp3/Transcription Factor Staining Buffer and stained with Alex Flour 488-conjugated 
phalloidin (Life Technologies) for F-actin and/or Alexa-Fluor 594-conjugated DNase I 
(Invitrogen: Molecular Probes) for G-actin. For analysis of phosphorylated Smad2/3, 
cells were stained with antibodies specific for CD4 and CD8, fixed with 1X BD Phosflow 
Lyse/Fix Buffer and permeabilized with BD Phosflow Perm Buffer III according to 
manufacturer’s instructions (BD Biosciences), then stained with anti-pSmad2/3 antibody 
(BD Biosciences). To detect Helios+ cells and expression of phosphorylated Stat5 
(pStat5), cells were immediately fixed with BD Phosflow Fix Buffer I for 10 minutes in a 
37°C water bath and surface stained with anti-CD25 (Clone 7D4; eBiosciences). Cell 
suspensions were permeabilized with BD Phosflow Perm Buffer III, according to 
manufacturer’s instructions (BD Biosciences), then stained with antibodies specific for 
CD4, CD8, Helios (eBiosciences) and pStat5 (Cell Signaling). Cells were collected on a 
FACSCalibur or LSRFortessa (BD Biosciences). Analysis was performed with FlowJo 
software (TreeStar, Inc.).  
 
 
Anti- CD3 and Soluble Anti-CD28 Stimulation 
 
Tissue culture-treated plates were incubated for one hour with 30µg/ml goat anti-
hamster IgG (Vector Laboratories) in PBS, then washed and incubated one hour with 
1µg/ml anti-CD3 (eBioscience). Plates were washed before addition of cells and 1µg/ml 
anti-CD28 (eBioscience) [4]. Alternatively, tissue culture-treated chambered coverglass 
slides were incubated with 0.01% solution of Poly-L-Lysine (Sigma-Aldrich), then 
washed and allowed to dry. Chambers were coated twice prior to treatment with hamster 
IgG and anti-CD3 as described above. Chamber slides were washed before the addition 
of cells and 1µg/ml anti-CD28.       
 
 
Stimulations of OT-I Cells 
 
Naïve (CD8+CD25-CD44loCD62Lhi) T cells were sorted from spleen and lymph 
nodes of OT-I and OT-I.Drak2-/- mice using the iCyt Reflection or Sy3200 Cell sorters.  
Naïve T cells were labeled with CFSE and stimulated in vitro with 100pM OVA257 
peptide-pulsed, CD45.1+ splenocytes that were irradiated at 3000 rads. Cells were 
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cultured in media only or media with TGF-β for two days, harvested, then analyzed by 
flow cytometry. 
  
Alternatively, 2 x 106 FACS-sorted, naïve (CD8+CD25-CD44loCD62Lhi) OT-I and 
OT-I.Drak2-/- T cells were stimulated for two days with 4.5 x 106 CD45.1+, irradiated 
splenocytes pulsed with 200 nM OVA257 peptide at 37°C. The cells were harvested, 
washed, and replated with naïve splenocytes in the presence of 5ng/ml TGF-β (R&D 
Systems) with or without 20 ng/ml recombinant mouse IL-2 (BD Biosciences), IL-7 
(Invitrogen Life Technologies), or IL-15 (R&D Systems). Two days later, fresh media 
and cytokines were added, and two days later, cells were harvested.  Cells were stained 
with antibodies specific for CD8, CD45.1, and CD45.2, followed by Annexin V, and 
analyzed by flow cytometry. 
 
 
Stimulation of OT-II Cells 
 
Single cell suspensions were prepared and sorted for naïve (CD4+CD25-CD44lo) T 
cells from spleen and lymph nodes of OT-II and OT-II.Drak2-/- mice. Naive CD4+ T cells 
were CFSE labeled and stimulated in vitro for three days with 10µM OVA323 peptide-
pulsed, irradiated splenocytes in the presence or absence of 10-fold TGF-β titrations. 
Cells were harvested, stained with viability dye and antibodies specific for CD4 and 
Foxp3, and analyzed for viability and proliferation by flow cytometry.  
 
 
Treg Induction 
 
In vitro Treg inductions were performed in two alternative ways. For the first 
analysis, single cell suspensions were prepared and sorted for naïve (CD4+CD25-CD44lo) 
T cells from spleen and lymph nodes of wildtype and Drak2-/- mice. Naïve CD4+ T cells 
were stimulated with 1µg/ml plate-bound anti-CD3 and 1 µg/ml soluble anti-CD28 for 72 
hours with 20ng/ml IL-2 and increasing amounts of TGF-β. For the second in vitro 
induction experiment, naïve OT-II and OT-II.Drak2-/- (CD4+CD25-CD44lo) T cells were 
purified and stimulated with irradiated splenocytes (loaded with 10uM OVA323 peptide) 
for 72 hours with increasing amounts of TGF-β (R&D Systems and Cell Signaling). Cells 
were harvested and analyzed for Foxp3 expression by flow cytometry.     
 
For in vivo Treg induction, naïve OT-II (CD45.1/CD45.2) and OT-II.Drak2-/- 
(CD45.2/CD45.2) T cells were sorted and combined at 1:1 ratio. Two million total T cells 
were transferred intravenously into wildtype (CD45.1/CD45.1) host mice. The following 
day, host mice were given water or water containing 2% ovalbumin ad libitum. 
Appropriate water treatments were replaced on day 2.5 and all mice were given water 
without ovalbumin on day 5. Organs were harvested five days after administration of 
ovalbumin and analyzed by flow cytometry for Foxp3 expression.  
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Microscopy 
 
For observation of anti-Smad2 expression using fluorescent microscopy, single 
cell suspensions were prepared and negatively selected by magnetic separation for CD4+ 
T cells from lymph nodes of wildtype and Drak2-/- mice. CD4+ T cells were stimulated 
for 24 hours with 1µg/ml anti-CD3 (coated onto poly L-lysine-treated coverglass slides) 
and 1µg/ml soluble anti-CD28. TGF-β was added to some samples for the final 20 
minutes. Cells were fixed with 4% methanol-free formaldehyde, permeabilized in 0.1% 
Triton-X in PBS, washed with PBS, and blocked with 1% BSA, followed by an overnight 
incubation with a primary rabbit antibody specific for Smad2 (Cell Signaling). Cells were 
stained with a secondary Alexa Fluor 647-conjugated goat anti-rabbit antibody, Alexa 
Fluor 488-conjugated phalloidin, and DAPI (Invitrogen Life Technologies). Images were 
collected utilizing a Nikon C1Si laser scanning confocal microscope. 
 
To conduct live cell imaging and mitotic analysis, single cell suspensions were 
prepared and negatively selected for CD4+ T cells from lymph nodes of wildtype and 
Drak2-/- mice and stimulated with 1µg/ml anti-CD3 (coated onto poly L-lysine-treated 
coverglass slides) and 1µg/ml soluble anti-CD28. For live cell imaging, CD4+ T cells 
were stimulated for a total of 36 hours, and images were collected in 6 minute increments 
beginning at 18 hours post-stimulation and ending at 36 hours. For mitotic analysis, cells 
were stimulated for 48 hours and fixed with a mixture containing 3 parts methanol and 1 
part acetic acid. Finally, cells were washed, permeabilized, stained with DAPI, and 
images were collected.  
 
 
Western Blot Analysis 
 
Single cell suspensions were prepared from spleen and lymph nodes of wildtype 
and Drak2-/- mice. Whole splenocytes and FACS-sorted naïve (CD25-CD44lo) CD4+ and 
CD8+ T cells were stimulated for two hours with plate-bound anti-CD3 and anti-CD28. 
Media with or without 2 ng/ml TGF-β was added to cells for one additional hour. Cells 
were harvested and frozen at -80°C. Frozen cell pellets were lysed (50mM Tris, 150mM 
NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 2mM EDTA, 10% glycerol with 
phosphatase and protease inhibitors (Calbiochem)). Protein concentration was determined 
using a BCA Protein Assay (Thermo Scientific). Equal amounts of protein were 
denatured in sample buffer (10% SDS, 20% Glycerol, 0.2M Tris HCl, 0.05% 
Bromophenol Blue), separated by SDS-PAGE, and transferred to PVDF membranes for 
immunoblot analysis of anti-Smad2, anti-pSmad2, and anti-HSP90 (Cell Signaling) 
expression.  
 
 
T Cell Adoptive Transfer 
 
Single cell suspensions were prepared and FACS sorted for naïve (CD25-
CD44loCD62Lhi) T cells from spleen and lymph nodes of female mice and injected 
intravenously via the tail vein into female recipient mice. Mice received 1.5 - 3.5 x 106 T 
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cells. For adoptive transfer experiments utilizing T cells from NOD or NOD.Drak2-/- mice 
expressing the islet antigen-specific BDC2.5 T cell receptor (TCR) transgene, 7,500 
naïve (CD4+CD25-CD44loCD62Lhi) T cells were transferred in the presence or absence of 
1 x 105 (CD4+CD25+CD45Rblo) NOD Tregs to recipient mice. Ten days following the 
injection, a sample of blood was analyzed to verify efficient transfer. Blood glucose was 
monitored weekly by testing a drop of venous tail blood with an OneTouch Ultra or 
Bayer Contour® blood glucose meter. Mice were considered diabetic after two 
consecutive readings of 290 mg/dL or greater. 
 
 
In Vitro Treg Suppression 
 
Single cell suspensions from spleen and lymph nodes of NOD and NOD.Drak2-/- 
mice were prepared and FACS-sorted for naïve (CD4+CD25-CD44loCD62Lhi) T cells. 
Cells were labeled with CFSE. Next, 50,000 labeled cells were stimulated with 15,000 or 
50,000 anti-CD3/CD28-coated T-Activator Dynabeads per well (0.3:1 or 1:1 
beads/effector T cell ratios, respectively; Life Technologies). Naive T cells were 
stimulated alone or with various ratios of NOD or NOD.Drak2-/- Tregs 
(CD4+CD25+CD45RBlo) for 72 hours. Cell viability was analyzed using fixable viability 
dye, and effector T cell proliferation was determined by measuring CFSE dilution of 
viable cells. 
 
 
In Vivo Treg Suppression 
 
Single cell suspensions prepared from spleen and lymph nodes of NOD mice 
(Thy1.1/Thy1.2) were FACS-sorted for naïve (CD4+CD25-CD44lo) T cells, CFSE-
labeled, and transferred intravenously into NOD.SCID mice (Thy1.2/Thy1.2) with or 
without NOD or NOD.Drak2-/- Tregs (CD4+CD25+CD45Rblo) (Thy1.1/Thy1.1) at a ratio 
of 4:1. Lymph nodes were harvested seven days after injection and analyzed for effector 
T cell proliferation to determine Treg suppression.  
 
 
Cell Cycle Analysis  
 
Single cell suspensions from the lymph nodes and spleen of wildtpye and Drak2-/- 
mice were FACS-sorted for naïve (CD4+CD25-CD44lo) T cells, then stimulated for 24 
hours with 1µg/ml plate-bound anti-CD3 and 1µg/ml soluble anti-CD28. Cells were 
harvested, washed once with PBS, then resuspended in propidium iodide solution (0.05 
mg/ml propidium iodide, 0.1% sodium citrate, 0.1% Triton X-100). Samples were treated 
with 10 µl of 0.2 mg/ml RNase (DNase-free) for 30 minutes at room temperature. 
Samples were filtered, then analyzed by flow cytometry.   
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Actin Gene Transcription 
 
Single cell suspensions were prepared from the lymph nodes and spleen of 
wildtype and Drak2-/- mice and sorted for naive (CD4+CD25-CD44lo) T cells. Naïve 
CD4+ T cells were stimulated with 1 µg/ml plate-bound anti-CD3 and 1 µg/ml soluble 
anti-CD28. Forty hours post-stimulation, RNA was extracted from cells with an RNeasy 
Mini Kit (Qiagen) and quantified using a NanoDrop 8000 Spectrophotometer (Thermo 
Scientific). Complementary DNA was synthesized from 500 ng RNA with TaqMan 
Reverse Transcription reagents (Applied Biosystems). The cDNA was analyzed by 
SYBR Green dye (Thermo Scientific) with primers for β-actin (Actb), and γ- actin 
(Actg1) using an Applied Biosystems 7500 Fast Real-Time PCR System. The amount of 
Actb and Actg1 transcripts was quantified by the relative standard curve method (User 
Bulletin 2; Applied Biosystems) and was normalized to GAPDH expression. 
 
 
Conjugation Assays  
 
Cell conjugation assays were performed as previously described [40,41], with 
modifications. Single cell suspensions from the spleen and lymph nodes of OT-I and OT-
I.Drak2-/- mice were FACS-sorted for naïve (CD8+CD44lo) T cells. In addition, single cell 
suspensions from the spleen of wildtype mice were prepared and pulsed with various 
concentrations of OVA257 peptide for 30 min at 37°C, then CFSE-labeled. Naïve CD8+ T 
cells and OVA257-loaded splenocytes were co-cultured at a 1:1 ratio, pelleted in a round-
bottom plate, and incubated for 10 minutes at 37°C. Cells were vortexed on a plate shaker 
for 20s, then fixed immediately with 1% paraformaldehyde. Finally, cells were stained 
with antibodies specific for B220 and CD8, and analyzed by flow cytometry. Antigen-
presenting cells (APCs) were characterized as B220+CFSE+ cells. Conjugates were 
electronically gated on APCs that were B220+CD8+.  
 
 
Migration Assays and CCL19 Treatment 
 
Transwell migration assays were performed as previously described [40,42], with 
modifications. Single cell suspensions from the lymph nodes of wildtype and Drak2-/- 
mice were negatively selected for CD4+ and CD8+ T cells using Miltenyi magnetic beads. 
T Cells were stimulated with 1µg/ ml anti-CD3 and 1µg/ml anti-CD28 for 2 hours. Cells 
were counted and equal numbers were added to a 96-well permeable support insert that 
was placed within receiver plate wells (Sigma-Aldrich, CLS3388), which contained 
either media only or 250 ng/ml CCL19 chemokine (Sigma-Aldrich). Migrated cells were 
recovered from the lower chamber and counted using a hemacytometer. The percentage 
of migrated T cells was determined by dividing the number of migrated cells by the 
number of input cells.  
 
Alternatively, for CCL19-mediated actin polymerization analysis, CD4+ and 
CD8+ T cells were negatively selected from the lymph nodes of wildtype and Drak2-/- 
mice and rested in culture media at 37°C for 20 minutes. Cells were treated with media 
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only or media with 250 ng/ml CCL19 for various time points between 0 and 30 minutes, 
then fixed immediately with BD Phosflow Fix Buffer I for 10 minutes in a 37°C water 
bath. Cells were washed and stained with anti-CD4 and anti-CD8 antibodies prior to 
treatment with 1X Permeabilization Buffer (eBioscience), according to manufacturer’s 
instructions. Finally, samples were stained with phalloidin and MFI expression was 
analyzed by flow cytometry.  
 
 
RAC-GTP Expression Analysis 
 
CD4+ and CD8+ T cells were negatively selected from the lymph nodes of 
wildtype and Drak2-/- mice. Cells were resuspended in HBSS (containing Ca2+ + 0.5% 
FCS) and incubated on ice for 30 minutes with 2µg of biotin-conjugated anti-CD3 and 
1.5 µg biotin-conjugated anti-CD28 (eBioscience) per 10 x 106 cells. Cells were 
stimulated by crosslinking biotin with 0.7 µg of prewarmed streptavidin per 10 x 106 cells 
and incubated in 37°C water bath. Stimulation was stopped by adding ice cold PBS and 
transferring cells to ice. Cells were washed, stained with antibodies specific for anti-CD4 
and anti-CD8, then fixed and permeabilized with the Foxp3/Transcription Factor Staining 
Buffer Set according to manufacturer’s instructions (eBioscience). Cells were stained 
with a primary mouse monoclonal antibody specific for active Rac-GTP (NewEast 
Biosciences), followed by a secondary anti-mouse PE-conjugated antibody. Cells were 
analyzed by flow cytometry. Rac-GTP expression for each genotype is normalized to 
each group’s Rac-GTP MFI at “0 minutes post-stimulation” (i.e. unstimulated cells). 
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CHAPTER 3.    DRAK2 CONTRIBUTES TO TYPE 1 DIABETES BY ALTERING 
REGULATORY T CELL DEVELOPMENT 
 
 
Introduction 
 
Type 1 diabetes (T1D) occurs when T cells and other cells of the immune system 
attack and destroy the insulin-producing, islet β-cells in the pancreas. Mice deficient in 
Drak2 are resistant to T1D when bred to the Non-obese diabetic (NOD) background [23]. 
NOD mice spontaneously develop diabetes, and disease etiology is similar to T1D in 
humans, including the involvement of autoreactive T cells, autoantibodies, and similar 
genetic risk factors [43]. Interestingly, despite the diminished autoimmunity, Drak2-/- 
mice effectively eliminate infectious pathogens and retain the ability to combat tumors 
similar to wildtype mice [23–26,32]. Thus, Drak2 is an ideal protein to target in order to 
treat autoimmune disorders without compromising immunity to pathogens and tumors. 
However, it is not clear exactly how Drak2 signaling contributes to autoimmunity.  
 
Drak2 is expressed highest in B cells and T cells [4,5,7]. In addition, Drak2 is also 
expressed in multiple tissues during development and in pancreatic β-cells after 
stimulation with free fatty acid (FFA) or cytokines [12–14]. We previously demonstrated 
that the resistance to T1D in NOD.Drak2-/- mice occurs because the Drak2-/- T cells do 
not accumulate in the pancreas to the same extent as wildtype NOD T cells [23]. T cell 
transfer experiments demonstrated that the defect in T cell accumulation was partly due 
to enhanced sensitivity to death in the absence of Drak2, which contributed to decreased 
T cell accrual in the pancreas and the pancreatic draining lymph nodes. Similarly, Ramos 
et al. found that Drak2-/- T cells were more susceptible to death following superantigen 
stimulation, and that overexpression of Bcl-x(L), an anti-apoptotic protein, in T cells 
rendered Drak2-/- mice susceptible to EAE [19]. These data suggest that Drak2 promotes 
the survival of autoreactive T cells, which contributes to autoimmune disease. However, 
it was not determined if the resistance to T1D in NOD.Drak2-/- mice was due solely to an 
increased susceptibility to death in the T cells, or if T cells were the central mediators of 
disease resistance in the NOD model. On the other hand, transgenic expression of Drak2 
in pancreatic β-cells rendered these cells more sensitive to apoptosis following in vitro 
stimulation [13]. Furthermore, mice that overexpressed Drak2 in the islet cells were more 
susceptible to diabetes in a streptozotocin-induced model [14]. These data suggest that 
Drak2 induces β-cell apoptosis, and that NOD.Drak2-/- mice may be resistant to T1D 
because the β-cells are less susceptible to apoptosis in the absence of Drak2.  
 
Therefore, we investigated whether the absence of Drak2 in the T cells, β-cells, or 
both cell types contributed to the resistance to T1D. We found that the resistance to T1D 
was due to Drak2-deficiency in the T cells, and that the absence of Drak2 in the 
pancreatic β-cells did not alter the incidence of T1D. Additionally, we show that the 
enhanced susceptibility to death of autoreactive NOD.Drak2-/- T cells was not the sole 
mediator of disease resistance, but that regulatory T cells (Tregs) were also required to 
prevent autoimmunity in NOD.Drak2-/- mice. Interestingly, NOD.Drak2-/- mice had a 
higher proportion of Tregs than NOD mice, which was due to enhanced IL-2 signaling 
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that increased the transition of Treg precursors into mature Tregs. These data provide 
novel insight into the etiology of T1D by showing that Drak2 not only contributes to 
autoimmune disease by enhancing survival of autoreactive T cells, but also reduces the 
proportion of Tregs through negative regulation of IL-2 signaling in thymocytes.  
 
 
Results 
 
 
The resistance to T1D in NOD.Drak2-/- mice transfers with the T cells and is 
independent of Drak2 expression in islet cells 
 
To test whether the absence of Drak2 in the β-cells or in the T cells contributes to 
T1D resistance in NOD.Drak2-/- mice, we performed T cell transfer experiments in which 
Drak2 was absent in the T cells, but not the β-cells. T cells were purified from NOD or 
NOD.Drak2-/- mice and transferred into NOD.SCID host mice. NOD.SCID mice lack 
functional T cells, but have normal expression of Drak2 in the islets. If the absence of 
Drak2 in the islets is required for disease resistance, then NOD.SCID mice receiving 
NOD.Drak2-/- T cells should develop T1D. Conversely, if the absence of Drak2 in the T 
cells contributes to disease resistance, then NOD.SCID mice receiving NOD.Drak2-/- T 
cells will not develop T1D. We found that NOD.SCID mice that received NOD.Drak2-/- T 
cells did not develop T1D, while all of the mice that received NOD T cells developed 
T1D by 24 weeks after T cell transfer (Figure 3-1A). This suggests that the absence of 
Drak2 in the T cells is important for resistance to T1D.  
 
To further explore whether Drak2 expression in the islets contributes to T1D 
disease resistance, we performed an additional cell transfer experiment in which Drak2 
was expressed in the transferred T cells, but not in the β-islet cells. Naïve T cells were 
sorted from NOD mice and transferred into either NOD.SCID or Drak2-/-.NOD.SCID host 
mice. If the absence of Drak2 in β-islet cells contributes to disease resistance, then we 
would expect Drak2-/-.NOD.SCID host mice to be less susceptible to disease than 
NOD.SCID host mice. We found that NOD.SCID and Drak2-/-.NOD.SCID host mice that 
received NOD T cells developed T1D with a similar incidence and frequency        
(Figure 3-1B). These data suggest that there is no protective effect for mice that lack 
Drak2 expression in the islets, and that expression of Drak2 in the T cells, rather than 
islet cells, plays a pivotal role in disease susceptibility.  
 
 
The resistance to T1D in NOD.Drak2-/- mice requires Tregs 
 
The resistance to T1D in NOD.Drak2-/- mice was due to the absence of Drak2 in 
the T cells. Although we previously showed that there was decreased accumulation and 
enhanced death in Drak2-/- T cells [23], we did not examine if this was the only factor 
contributing to autoimmune disease resistance. Therefore, we next tested whether Tregs  
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Figure 3-1. The resistance to T1D in NOD.Drak2-/- mice transfers with the T cells 
and is independent of Drak2 expression in islet cells. 
 
(A) T cells were purified from lymph nodes and spleen of female NOD or NOD.Drak2-/- 
mice and transferred into NOD.SCID host mice. Mice were monitored weekly for 
diabetes by testing glucose levels in the blood. Incidence of diabetes for six mice 
receiving NOD or NOD.Drak2-/- T cells is plotted. Data were analyzed with a Log-rank 
(Mantel-Cox) test, P = 0.0005, and are representative of two independent experiments. 
(B) Naive T cells from NOD mice were transferred into NOD.SCID or Drak2-/-
.NOD.SCID mice. The host mice were monitored weekly for diabetes. Diabetes incidence 
for ten mice per group is plotted.  Data represent two combined experiments and were 
analyzed with a Log-rank (Mantel-Cox) test, P = 0.7907  
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were required for the resistance to T1D in NOD.Drak2-/- mice, or whether the resistance 
was due solely to enhanced death of Drak2-/- effector T cells. We sorted conventional T  
 (Tconv) cells from NOD or NOD.Drak2-/- mice and transferred them into NOD.SCID mice 
in the absence of Tregs. As the transfer of effector T cells without Tregs into 
lymphopenic NOD.SCID hosts can induce colitis and other autoimmune symptoms prior 
to diabetes onset, we recorded the incidence of mice that developed T1D, colitis, or 
dermatitis. In the absence of Tregs, NOD.Drak2-/- effector T cells induced autoimmunity 
to the same extent as NOD effector T cells, suggesting that Tregs are required for the 
resistance to autoimmunity in Drak2-/- mice (Figure 3-2A). To examine the incidence 
specifically of T1D in the absence of Tregs, we transferred a small number of 
NOD.BDC2.5 TCR transgenic T cells, which are specific for an islet autoantigen. 
NOD.BDC2.5 and Drak2-/-.NOD.BDC2.5 Tconv cells were sorted and transferred into 
NOD.SCID mice. We found that in the absence of Tregs, both NOD.BDC2.5 and Drak2-/-
.NOD.BDC2.5 Tconv cells induced T1D, although there was a delay in T1D onset in mice 
receiving Drak2-/-.NOD.BDC2.5 Tconv cells (Figure 3-2B). These data suggest that Tregs 
are required for the resistance to T1D in NOD.Drak2-/- mice, but that enhanced 
susceptibility to death of the Drak2-/- effector T cells also contributes to the resistance to 
T1D, as disease onset was delayed in the group receiving Drak2-/-.NOD.BDC2.5 Tconv 
cells.   
 
To test whether the addition of Tregs to the Drak2-/-.NOD.BDC2.5 Tconv cells 
could restore the resistance to T1D, we transferred NOD.BDC2.5 or Drak2-/-
.NOD.BDC2.5 Tconv cells with NOD Tregs into NOD.SCID host mice. The addition of 
Tregs along with Drak2-/-.NOD.BDC2.5 Tconv cells rescued T1D disease resistance 
completely, whereas the addition of Tregs to NOD.BDC2.5 Tconv cells did not prevent 
T1D (Figure 3-2C). These data further suggest that in NOD.Drak2-/- mice, complete 
resistance to T1D requires Tregs in cooperation with enhanced T effector cell death.  
 
 
NOD.Drak2-/- Tregs function similar to NOD Tregs 
 
Given that Tregs were required to elicit resistance to T1D in NOD.Drak2-/- mice, 
we examined whether the function of Tregs was augmented in the absence of Drak2. 
NOD effector T cells were stimulated and cultured alone or with increasing ratios of 
NOD or NOD.Drak2-/- Tregs. We found that NOD and NOD.Drak2-/- Tregs suppressed in 
vitro T effector cell proliferation to a similar extent (Figure 3-3A). To confirm this 
finding in vivo, we transferred naïve, NOD T cells into NOD.SCID mice and examined 
the ability of NOD or NOD.Drak2-/- Tregs to inhibit homeostatic proliferation of the 
NOD effector T cells. The percent and number of live, divided NOD effector T cells 
decreased in the presence of both NOD and NOD.Drak2-/- Tregs (Figure 3-3B). 
Importantly, there was not a significant difference in the ability of NOD and  
NOD.Drak2-/- Tregs to suppress effector T cell proliferation. These data suggest that 
NOD and NOD.Drak2-/- Tregs function similarly, and therefore Drak2 does not affect the 
suppressive function of Tregs.   
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Figure 3-2. The resistance to T1D in NOD.Drak2-/- mice requires Tregs. 
 
(A) Three million purified CD25-CD45RBhi conventional T (Tconv) cells from NOD or 
NOD.Drak2-/- mice were transferred into NOD.SCID mice in the absence of Tregs. Host 
mice were monitored weekly for diabetes, dermatitis, or colitis. The incidence of any one 
of these symptoms in five mice that received NOD or NOD.Drak2-/- T cells is plotted. 
Data were analyzed with a Log-rank (Mantel-Cox) test, P = 1.00, and are representative 
of three independent experiments. (B) Naive NOD.BDC2.5 or Drak2-/-.NOD.BDC2.5 
Tconv cells were transferred into NOD.SCID mice in the absence of regulatory T cells. The 
host mice were monitored for diabetes. Diabetes incidence in 3-4 mice per group is 
shown. Data were analyzed with a Log-rank (Mantel-Cox) test, P = 0.2412, and are 
representative of two experiments. (C) NOD Tregs were transferred with naive 
NOD.BDC2.5 or Drak2-/-.NOD.BDC2.5 Tconv cells into NOD.SCID mice. The incidence 
of diabetes in 3-4 mice per group is shown. Data were analyzed with a Log-rank (Mantel-
Cox) test, P = 0.0736, and are representative of one experiment.  
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Figure 3-3. NOD.Drak2-/- Tregs function similar to NOD Tregs. 
 
(A) Naïve NOD T cells were purified, CFSE labeled, and stimulated with anti-CD3/anti-
CD28 coated beads in vitro either alone or mixed at various ratios with NOD or 
NOD.Drak2-/- Tregs. The number of live, divided T effectors is shown. Samples were 
plated in triplicate and error bars represent standard deviation. There was no significant 
difference between samples that included NOD or NOD.Drak2-/- Tregs as determined by 
two-way ANOVA analysis with Bonferroni post-tests. Data are representative of 6 
experiments.  (B) Naive NOD T cells were transferred into NOD.SCID host mice alone or 
mixed at a 4:1 ratio with either NOD or NOD.Drak2-/- Tregs. The percent and number of 
live, divided T effectors, 7 days after injection, are shown for 4 mice per group, and error 
bars represent SEM. Data were analyzed using the Mann-Whitney test and there was no 
significant difference between mice that received NOD or NOD.Drak2-/- Tregs. Data are 
representative of three independent experiments.  (C) Naive NOD or NOD.Drak2-/- T 
cells were purified, CFSE labeled, and stimulated with anti-CD3/anti-CD28 coated beads 
in vitro either alone or mixed at various ratios with NOD Tregs. The number of live, 
divided T effectors is shown. Samples were plated in triplicate and error bars represent 
standard deviation. There was no significant difference between samples in response to 
NOD Tregs as determined by two-way ANOVA analysis with Bonferroni post-tests. Data 
are representative of four experiments.    
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Since the addition of Tregs enhanced disease resistance when transferred with 
Drak2-/-.NOD.BDC2.5 Tconv cells, to a greater extent than NOD.BDC2.5 Tconv cells 
(Figure 3-2C), we tested whether Tconv cells were more susceptible to Treg-mediated 
suppression in the absence of Drak2. NOD and NOD.Drak2-/- T cells were stimulated and  
cultured in vitro alone or with increasing ratios of NOD Tregs. We found that NOD and 
NOD.Drak2-/- T effectors were suppressed similarly in response to NOD Tregs in  
vitro. These data suggest that T effectors are not more susceptible to Treg suppression in 
the absence of Drak2.   
 
 
Drak2-/- mice exhibit an increase in the proportion of Foxp3+CD4+ Tregs compared 
to wildtype mice 
 
Since the T cell transfer experiments indicate that Drak2 mediates autoimmunity 
within T cells, and that Tregs are required, we investigated whether there were 
differences in the proportion of Tregs in NOD.Drak2-/- mice compared to NOD mice. We 
previously examined Foxp3 expression in a very small group of 10-12 week old NOD 
mice. While we did observe a trend towards an increase in Foxp3+CD4+ cells in 
NOD.Drak2-/- mice compared to NOD mice, this difference was not statistically 
significant [23]. Therefore, we further explored the Treg populations in a larger cohort of 
mice. Analysis of the thymus, spleen, peripheral lymph nodes, pancreatic lymph nodes 
(LN), and pancreas from 13-week-old NOD and NOD.Drak2-/- mice showed that the 
proportion of CD4+ cells in the lymphoid organs that were Foxp3+ Tregs was 
significantly increased in NOD.Drak2-/- mice compared to NOD mice (Figure 3-4A).  
 
The increased proportion of Tregs in the NOD.Drak2-/- mice could be due to 
enhanced induction of Tregs in the periphery as a result of inflammation caused by T 
cells infiltrating the pancreas. Therefore, we analyzed lymphoid organs from four week 
old mice, which is prior to the onset of insulitis. Similar to the 13 week old mice, we 
found that the proportion of CD4+ T cells that were Foxp3+ was significantly increased in 
four week old NOD.Drak2-/- mice compared to NOD mice (Figure 3-4B), suggesting that 
the difference in the proportion of Tregs is not due to insulitis or diabetes in the NOD 
mice. 
 
We previously analyzed the number and proportion of Tregs in C57BL/6 mice 
during the course of EAE and did not see an increase in Tregs in Drak2-/- mice compared 
to wildtype mice. We did observe that prior to induction of EAE, there were more Tregs 
in the Drak2-/- mice compared to wildtype mice, however we did not analyze enough 
mice to ascertain whether the difference was significant [23]. Therefore, we also 
examined the lymphoid organs of C57BL/6 mice to determine whether the absence of 
Drak2 altered the proportion of Tregs in this strain.  We found that, similar to NOD mice, 
there was a significant increase in the proportion of CD4+ T cells that expressed Foxp3 in 
the absence of Drak2 in the thymus and spleen of C57BL/6 mice (Figure 3-4C). These 
data suggest that Drak2 may play a role in Treg development or in the induction of Tregs 
prior to autoimmunity, and that this function of Drak2 is not restricted to the NOD  
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Figure 3-4. Drak2-/- mice exhibit an increase in the proportion of Foxp3+CD4+ 
Tregs compared to wildtype mice. 
  
Cells were harvested from the various organs at (A) 13 weeks of age and (B) 4 weeks of 
age, and (C) 4-6 weeks of age, and stained with antibodies specific for Foxp3 and CD4. 
The percent of Foxp3+ cells of electronically gated, viable CD4+ cells is shown for each 
organ. (A) Data represent two combined experiments with 13-15 mice per group. (B) 
Data are representative of three experiments with at least 7 mice per group. (C) Data are 
representative of three experiments with at least 5 mice per group. All data were analyzed 
using Mann-Whitney U test (two-tailed) and error bars represent SEM. *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001, ****P ≤ 0.0001. 
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background. Furthermore, as we observed the increased Treg proportion prior to disease  
onset, the early impact of Drak2 on the proportion of Tregs may have long-term effects 
on autoimmune disease outcome.  
 
 
The induction of Tregs is not enhanced in the absence of Drak2 
 
 The increase in Tregs in the NOD.Drak2-/- mice could be due to an enhanced 
development of Tregs in the thymus or due to an increased induction of Tregs in the  
periphery. Thus, we investigated whether Drak2 affects the induction of Tregs utilizing 
both in vitro and in vivo methods. Naïve OT-II and OT-II.Drak2-/- CD4+ T cells were 
activated in vitro with OVA323-pulsed splenocytes in the presence or absence of TGF-β. 
We did not observe an enhanced induction of Tregs in the OT-II.Drak2-/- CD4+ T cells 
compared to OT-II CD4+ T cells, indicating that the induction of Tregs was not enhanced 
in the absence of Drak2 (Figure 3-5A). To determine if Treg induction was enhanced in 
vivo, we transferred naive OT-II and OT-II.Drak2-/- conventional T cells, mixed at a 1:1 
ratio, into congenically marked host mice. The host mice were then given water with or 
without 2% Ovalbumin, which elicits proliferation of transferred OT-II cells, as well as 
induction of Foxp3+CD4+ Tregs. Similar to the in vitro induction experiment, the percent 
and number of induced Foxp3+CD4+ Tregs in the spleen and lymph nodes was 
comparable between OT-II and OT-II.Drak2-/- cells (Figure 3-5B). While there was a 
slight, yet significant decrease in the percent of induced Foxp3+CD4+ Tregs in OT-
II.Drak2-/- CD4+ T cells compared to OT-II CD4+ T cells in the mesenteric lymph nodes, 
similar numbers were observed. These data indicate that the induction of Tregs was not 
enhanced in the absence of Drak2. Together these data suggest that the increased 
proportion of Tregs in NOD.Drak2-/- mice is not due to enhanced induction in the 
periphery, but rather may be the result of augmented development of Tregs in the thymus. 
 
 
The proportion of precursor Tregs is comparable between wildtype and Drak2-/- 
thymocytes in NOD and C57BL/6 mice 
 
Given that the absence of Drak2 did not enhance the induction of Tregs, we 
explored whether the absence of Drak2 altered Treg development in the thymus. The 
development of thymic Tregs occurs in a two-step process in which TCR engagement 
and CD28 co-stimulation induces the development of CD4+CD25+Foxp3- precursor 
Tregs. Then, IL-2 signals mediate the transition from precursor Tregs into mature 
CD4+CD25+Foxp3+ Tregs [44,45]. To determine if there was an increase in precursor 
Tregs in the absence of Drak2, we analyzed NOD and NOD.Drak2-/- CD4+CD8- 
thymocytes for the proportion of precursor and mature Tregs. The proportion of mature 
Tregs was significantly increased in 1 week old and 5 week old NOD.Drak2-/- mice 
compared to NOD mice, similar to our previous experiments (Figure 3-4). However, the 
proportion of precursor Tregs was similar in both groups (Figure 3-6A and 3-6B). 
Likewise, 4-6 week old C57BL/6.Drak2-/- mice displayed an increase in the proportion of 
mature Tregs, but not Treg precursors compared to C57BL/6 mice. These data suggest 
that the first stage of Treg development is not affected by Drak2, but that the transition  
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Figure 3-5. The induction of Tregs is not enhanced in the absence of Drak2.  
 
(A) CD4+CD25-CD44lo naïve T cells were purified from the spleen and lymph nodes of 
OT-II and OT-II.Drak2-/- mice and stimulated with irradiated, OVA323 peptide-pulsed 
splenocytes in the presence or absence of 10-fold TGF-β titrations. Three days later, cells 
were harvested, stained with antibodies specific for CD4 and Foxp3, and analyzed by 
flow cytometry. The percent and number of Foxp3+ cells of electronically gated, viable 
CD4+ cells are shown. Cells were tested in quadruplicate and error bars indicate standard 
deviation. There was no significant difference between samples in response to TGF-β-
mediated Foxp3 induction as determined by two-way ANOVA analysis with Bonferroni 
post-tests. Data are representative of five separate experiments. (B) CD4+CD25-CD44lo 
naïve OT-II and OT-II.Drak2-/- T cells were mixed at a 1:1 ratio and intravenously 
injected into congenically marked wildtype host mice. Host mice received either water 
containing 2% ovalbumin or water alone for 5 days. Spleen, peripheral lymph nodes 
(LN), and mesenteric lymph nodes (mLN) were harvested on day 6. Cells from 3 mice 
per group were analyzed by flow cytometry for Foxp3 expression of electronically gated, 
viable OT-II CD4+ T cells. Data were analyzed using an unpaired t-test, *P = 0.0287, and 
are representative of three independent experiments.  
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Figure 3-6. The proportion of precursor Tregs is comparable between wildtype 
and Drak2-/- thymocytes in NOD and C57BL/6 mice.  
 
Cells were harvested from the thymus of NOD, NOD.Drak2-/-, C57BL/6, and 
C57BL/6.Drak2-/- mice of various ages and stained with antibodies specific for CD4, 
CD8, CD25, and Foxp3. (A) Representative flow cytometry plots of electronically gated, 
viable CD4+CD8- thymocytes are shown.  (B) The percent of CD25+Foxp3- precursor 
Tregs or Foxp3+ mature Tregs of electronically gated CD4 single positive (SP) cells is 
shown for at least 4 mice per group. Data are representative of at least three independent 
experiments and were analyzed using Mann-Whitney test (two-tailed). Error bars 
represent SEM.  (C) Cells were harvested from the thymus of 1 day old NOD.Drak2+/- 
and NOD.Drak2-/- mice and stained with antibodies specific for CD4, CD8, CD25, and 
Foxp3. Representative flow cytometry plots of electronically gated CD4+CD8- 
thymocytes are shown. Bar graphs show percent of CD25+Foxp3- precursors and Foxp3+ 
mature Tregs of electronically gated, viable CD4 SP cells from at least 3 mice per group 
and are representative of two independent experiments. Data were analyzed using an 
unpaired t-test and error bars represent SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
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from precursor Treg to mature Treg may be enhanced in the absence of Drak2. To further 
confirm that Drak2 affects Treg development, rather than induction, we examined  
precursor and mature Treg populations in 1 day old NOD.Drak2+/- and NOD.Drak2-/- 
neonates. Similar to comparisons between older NOD and NOD.Drak2-/- mice, we found 
that during this very early stage of T cell development, there were comparable 
proportions of precursor Tregs, but enhanced frequencies of mature Tregs in the absence 
of Drak2 (Figure 3-6C). These data further suggest that Drak2 plays a role in early 
Foxp3 induction and the development of Tregs. 
 
 
NOD thymocytes are more sensitive to IL-2 signaling in the absence of Drak2 
 
As the transition from precursor Treg to mature Treg is mediated by IL-2, we 
examined if IL-2 signaling was enhanced in NOD.Drak2-/- thymocytes. NOD.Drak2+/- 
and NOD.Drak2-/- thymocytes from 1 day old mice were cultured in vitro with IL-2 and 
analyzed for phosphorylation of Stat5, a transcription factor that is critical for IL-2-
mediated Foxp3 induction and Treg development [46]. Interestingly, a greater proportion 
of NOD.Drak2-/- CD4+CD25+ thymocytes expressed phosphorylated Stat5 in response to 
IL-2 compared to NOD.Drak2+/- thymocytes (Figure 3-7A and 3-7B). Because 
CD4+CD25+ thymocytes include both precursor and mature Tregs, we investigated 
whether these two populations exhibited comparable responses to IL-2 in the absence of 
Drak2. To distinguish between these populations, we used expression of the transcription 
factor, Helios, to identify mature thymic Tregs because the reagents used to stain for 
pStat5 were incompatible with Foxp3 staining. Interestingly, we found that in response to 
IL-2, the proportion of pStat5+ precursor Tregs was significantly enhanced in the absence 
of Drak2, while the proportion of NOD and NOD.Drak2-/- mature Tregs that 
phosphorylated Stat5 was similar (Figure 3-7C). These data suggest that, in the absence 
of Drak2, enhanced IL-2 signaling via Stat5 in precursor Tregs increases the transition of 
these cells into mature Tregs. To examine whether the enhanced IL-2 signaling in the 
NOD.Drak2-/- thymocytes was due to differences in the expression level of CD25, a 
component of the high affinity IL-2 receptor complex, we compared the mean 
fluorescence intensity (MFI) of CD25 on CD25+CD4 SP thymocytes, precursor Tregs, 
and mature Tregs from NOD.Drak2+/- and NOD.Drak2-/- mice. The expression of CD25 
was not increased on these subsets in NOD.Drak2-/- mice compared to NOD.Drak2+/- 
mice, indicating that the enhanced IL-2 signaling is not due to increased CD25 expression 
in the absence of Drak2 (Figure 3-7D).  
 
To determine if enhanced IL-2 signaling leads to the enhanced proportion of 
Foxp3-expressing cells in the absence of Drak2, we cultured NOD.Drak2+/- and 
NOD.Drak2-/- thymocytes from 1 day old mice with increasing amounts of IL-2 for 24 
hours. Interestingly, we found that a greater the proportion of NOD.Drak2-/- CD4 SP cells 
upregulated Foxp3 in response to IL-2 compared to NOD CD4 SP cells (Figure 3-7E). 
Together these data show that in the absence of Drak2, IL-2 signaling is enhanced in 
precursor Tregs, which induces increased phosphorylation of Stat5 and Foxp3 expression. 
Thus, more precursor Tregs transition into mature Tregs during development in the  
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Figure 3-7. NOD thymocytes are more sensitive to IL-2 signaling in the absence of 
Drak2.  
 
(A) Thymocytes were harvested from 1 day old NOD.Drak2+/- and NOD.Drak2-/- mice 
and incubated for 20 minutes with media alone (0 ng/ml IL-2) or with 16 ng/ml 
recombinant mouse IL-2. Representative flow cytometry plots of electronically gated, 
viable CD4+CD8-CD25+ thymocytes are shown. Numbers indicate percent of CD4+CD8-
CD25+ cells that express phosphorylated Stat5 (pStat5) (B-C) Thymocytes from 1 day 
old NOD.Drak2+/- and NOD.Drak2-/- mice were incubated for 20 minutes with media 
alone or with increasing concentrations of IL-2. Cells were harvested and stained with 
antibodies specific for CD4, CD8, CD25, and Helios and analyzed by flow cytometry. 
(B) The percent of pStat5+ cells of electronically gated, viable CD4+CD8-CD25+ 
thymocytes is shown. (C) The percent of pStat5+ of Helios- (Precursor Tregs) and Helios+ 
(Mature Tregs) of electronically gated, viable CD4+CD8-CD25+ thymocytes is shown. 
Data were analyzed using two-way ANOVA with Bonferroni post-tests and error bars 
represent SEM.  (D) Thymocytes were stained with anti-CD4, anti-CD8, anti-CD25, and 
anti-Foxp3 and analyzed by flow cytometry. The mean fluorescence intensity of CD25 
expression is shown for CD25+CD4+CD8- cells, CD4+CD8-CD25+Foxp3- (Precursor 
Tregs) and CD4+CD8-Foxp3+ (Mature Tregs). Data were analyzed using an unpaired t-
test and are representative of 2 independent experiments with at least 3 mice per group. 
(E) Thymocytes were incubated for 24 hours with media alone or with increasing 
concentrations of IL-2. Cells were harvested and stained with antibodies specific for 
CD4, CD8, CD25, and Foxp3, along with fixable viability dye.  The percent Foxp3+ cells 
of electronically gated, viable CD4+CD8- cells is shown for at least 3 mice per group. 
Data were analyzed using two-way ANOVA with Bonferroni post-tests and error bars 
represent SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
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thymus, in the absence of Drak2. This enhanced proportion of Tregs contributes to the 
resistance to T1D in the NOD.Drak2-/- mice. 
 
 
Discussion 
 
Drak2 plays a critical role in the induction of autoimmunity, but does not impact 
immunity to infectious pathogens and tumors. Therefore, Drak2 is an ideal protein to  
target to treat diseases such as T1D and MS without causing generalized immune 
suppression. Further insight into the immunological functions by which Drak2 impacts 
autoimmunity is important in order to understand the multiple checkpoints that work 
together to prevent autoimmune disease. We and others previously demonstrated  
that the resistance to autoimmunity in Drak2-/- mice was partly due to increased 
susceptibility to death in T cells following activation [19,23]. This increased T cell death 
resulted in fewer autoreactive T cells and less accumulation in the target organ. The data 
presented here show that this increased susceptibility to death of Drak2-/- T cells was not 
sufficient to prevent autoimmune disease, and that the presence of Tregs was also 
required for NOD.Drak2-/- mice to be resistant to T1D. Further, we show that in the 
absence of Drak2, there was an increase in the proportion of Tregs due to increased IL-2 
signaling via Stat5 in thymic precursor Tregs. Although the increase in the proportion of 
Tregs in the absence of Drak2 was small, this increase was consistently significant in 
mice of various ages and of two independent background strains. Given that Tregs were 
required for the resistance to T1D in the NOD.Drak2-/- mice, these data suggest that a 
small increase in the proportion of Tregs, along with an increased sensitivity to death of 
the effector T cells together prevent T1D.  
 
 Our data indicate that Drak2 reduces the development of Tregs in the thymus by 
negatively regulating IL-2 signaling in CD4 SP cells. This was evident by the fact that 
there was an increased proportion of Tregs in NOD.Drak2-/- mice as early as one day of 
age, and that more of the NOD.Drak2-/- thymocytes phosphorylated Stat5 in response to 
IL-2 compared to NOD thymocytes. This is similar to Traf3-/- thymocytes that display an 
increased transition from precursor to mature Treg due to enhanced IL-2 signaling [47]. 
Traf3 reduces IL-2 signaling by recruiting the tyrosine phosphatase, TCPTP, to the IL-2 
receptor complex, in turn, reducing activation of Jak1, Jak3, and Stat5. The finding that 
more cells phosphorylate Stat5 in the absence of Drak2 suggests that Drak2 blocks IL-2 
signaling upstream of Stat5 activation (Figure 3-8). Similar to Traf3, Drak2 may also act 
as a scaffold to recruit negative regulators of IL-2 signaling such as SOCS1, SOCS3, or 
SHP-1 to the receptor complex, or may play a role in the induction of one of these 
negative regulators. In addition, Drak2 may block recruitment of Jak1 or Jak3 to the IL-2 
receptor complex. The exact mechanism by which Drak2 reduces pStat5-mediated Foxp3 
induction following IL-2 signaling must be further explored. Interestingly, enhanced IL-2 
signaling also renders mature T cells more susceptible to apoptosis [48], and we 
previously demonstrated that Drak2-/- T cells produced more IL-2 than wildtype T cells 
after stimulation [4]. Thus, an intriguing possibility is that the enhanced susceptibility to 
apoptosis of mature, autoreactive Drak2-/- T cells may also be due to increased IL-2 
signaling, a concept that also requires further study. 
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Figure 3-8. Proposed model of Drak2 function in IL-2 signaling. 
 
Drak2 is a negative regulator of IL-2 signaling upstream of Stat5 during Treg 
development in the thymus.  Negative regulatory effects lead to decreased Stat5 
phosphorylation and decreased Foxp3 gene transcription. As a result, fewer regulatory 
Tregs develop, which contributes to enhanced autoimmunity. 
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Others reported that Drak2 is expressed in pancreatic β-cells following 
stimulation with cytokines or FFA, and this may contribute to the resistance to T1D in 
NOD.Drak2-/- mice [13]. However, our data show that transfer of NOD T cells into  
mice that lack Drak2 in the β-cells still results in T1D, suggesting that the absence of 
Drak2 in the β-cells does not render mice more resistant to T1D. Furthermore, transfer of 
NOD T cells, but not NOD.Drak2-/- T cells, into NOD.SCID mice caused T1D, again 
suggesting that the resistance to T1D was due to the absence of Drak2 in the T cells,  
rather than the β-cells. While Drak2 overexpression increased β-cells death in vitro and 
increased the susceptibility of mice to streptozotocin-induced diabetes, the expression of 
Drak2 in the β-cells was not important for resistance to T1D in NOD mice. 
 
Based on our data, and that of others, Drak2 is a promising target to treat 
autoimmune diseases. Studies showed that exogenous IL-2 treatment offers protection 
against T1D in NOD mice primarily by maintaining Tregs [49]. In addition, reduced IL-2 
production and consequent Treg dysfunction was reported in T1D patients [50]. Thus, it 
is an intriguing possibility that therapeutic inhibition of Drak2 may enhance IL-2 
signaling and benefit downstream functional effects of IL-2 in the treatment of T1D. 
Inhibition of Drak2 in patients initially after diagnosis may also prevent further β-cell 
destruction by not only decreasing the number of autoreactive T cells via enhanced 
susceptibility to death, but it may also boost the proportion of protective Tregs through 
increased IL-2 signaling. In this way, the β-cells would be preserved, which would 
maintain insulin production. In T1D patients already suffering from significant β-cell 
destruction, Drak2 inhibition could be used along with therapies that enhance the 
generation of β-cells, to prevent T cell destruction of these newly generated cells. While 
much progress has been made in inducing the development of β-cells, if the T cells that 
destroy the β-cells are not inhibited, these therapies will not have long-term success.  
 
Together the data presented here offer important insight into the role of Drak2 in 
T1D. First, the absence of Drak2 in the T cells, and not the β-cells contributes to the 
resistance to T1D. Therefore, the molecular mechanisms in which Drak2 functions 
should be further explored in T cells rather than β-cells. In addition, enhanced IL-2 
signaling via Stat5 increases Foxp3 expression and development of Tregs, which 
contributes to the resistance to T1D in the NOD.Drak2-/- mice. Thus, Drak2 impacts 
autoimmunity by decreasing the proportion of Tregs, along with enhancing the survival 
of autoreactive T cells.  
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CHAPTER 4.    DRAK2 DOES NOT REGULATE TGF-ΒETA SIGNALING        
IN T CELLS* 
 
 
Introduction 
 
Drak2 has been shown to interact with several proteins in in vitro recombinant 
assays and in cell lines. These proteins include myosin light chain [7], protein kinase C-γ 
[16], protein kinase D, p70S6 [14], CHP [9], and transforming growth factor-β receptor I 
(TGF-βRI) [10]. However, most of these interactions were based on overexpression 
experiments in cell lines and have not been confirmed in T cells. Therefore, it is not clear 
which of these interactions may affect autoimmune disease. 
 
As TGF-β is a critical suppressor of autoimmunity, the interaction of Drak2 and 
the TGF-βRI is an intriguing possibility to explain how Drak2 contributes to 
autoimmunity. TGF-β is a pleiotropic cytokine that elicits numerous effects on various 
cell types [51]. In T cells specifically, TGF-β inhibits proliferation of naïve T cells, 
induces development of regulatory T cells, and enhances apoptosis of activated T cells. A 
recent study proposed that Drak2 functions as a negative regulator of TGF-β signaling by 
inhibiting the phosphorylation and recruitment of Smad2 and Smad3 to the TGF-βRI in 
cell lines [10]. Thus, the absence of Drak2 in T cells may render these cells more 
susceptible to TGF-β signaling, which could prevent autoimmunity. However, it has not 
been tested if Drak2 functions as a negative regulator of TGF-β in T cells, and 
consequently, whether Drak2-/- T cells are more sensitive to TGF-β signaling. 
 
Therefore, we investigated whether Drak2 functions as a negative regulator of 
TGF-β signaling in T cells, and further if the enhanced susceptibility to apoptosis in 
Drak2-/- T cells was due to augmented TGF-β signaling. We found that TGF-β signaling 
via Smad2 and Smad3 was not enhanced in the absence of Drak2 in T cells, and that 
Drak2-/- T cells did not exhibit enhanced responses to TGF-β signaling during in vitro 
assays. These data suggest that Drak2 does not function as an inhibitor of TGF-β 
signaling in T cells. Moreover, in the absence of TGF-β signaling, Drak2-/- T cells 
remained more susceptible to apoptosis, suggesting that the increase in cell death 
observed in vitro, was not due to enhanced TGF-β-mediated signals. These data provide 
insight into the role of Drak2 in autoimmune diseases by showing that Drak2 does not 
suppress TGF-β signaling in T cells, and therefore may contribute to autoimmune disease 
via other molecular pathways. 
__________________________ 
 
*Reprinted with permission. Harris TL, McGargill MA. Drak2 Does Not Regulate TGF-β 
Signaling in T Cells. PLoS ONE. 2015;10(5):e0123650 [52]. 
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Results 
 
 
TGF-β signaling via Smad proteins is not enhanced in Drak2-/- T cells compared to 
wildtype T cells 
 
Given that recent experiments in cell lines suggested that Drak2 negatively 
regulates TGF-β signaling [10], and enhanced TGF-β signaling in T cells could 
contribute to the resistance to autoimmune disease, we tested whether Drak2 functions as 
a negative regulator of TGF-β signaling in T cells. TGF-β receptor engagement results in 
the phosphorylation of the Smad2/Smad3 signaling complex, which then translocates 
from the cytoplasm into the nucleus to facilitate transcription of TGF-β target genes. To 
determine if Smad2 translocation into the nucleus was increased in the absence of Drak2, 
we activated CD4+ T cells with anti-CD3 and anti-CD28 antibodies for 24 hours, and 
then utilized confocal fluorescent microscopy to analyze Smad2 localization following 
addition of TGF-β. As expected, Smad2 translocation into the nucleus was not observed 
in stimulated T cells without exogenous TGF-β (Figure 4-1). The addition of TGF-β 
during the final 20 minutes of culture elicited Smad2 translocation into the nuclear region 
of both wildtype and Drak2-/- T cells (Figure 4-1). Importantly, there were no differences 
in Smad2 translocation between wildtype and Drak2-/- T cells in response to exogenous 
TGF-β. 
 
We also examined phosphorylation of Smad2 by western blot in lysates from 
purified CD4+ T cells, CD8+ T cells, or whole splenocytes. In all cell types, Smad2 was 
phosphorylated in response to TGF-β treatment; however, the extent of phosphorylation 
was not increased in Drak2-/- cells compared to wildtype cells (Figure 4-2A). Finally, to 
determine if Drak2-/- cells are hypersensitive to lower concentrations of TGF-β, we 
analyzed the phosphorylation of the Smad2/Smad3 complex by flow cytometry in 
response to decreasing amounts of TGF-β. Again, even at the lower doses of TGF-β, the 
phosphorylation of Smad2/3 was similar in wildtype and Drak2-/- cells (Figure 4-2B). 
Together, these data show that Drak2-/- T cells do not exhibit enhanced TGF-β signaling 
via Smad2 or Smad2/3 complex phosphorylation compared to wildtype T cells, 
suggesting that Drak2 does not function as a negative regulator of TGF-β signaling in 
primary T cells activated in vitro. 
 
 
The effects of TGF-β on T cells are comparable between wildtype and Drak2-/- T 
cells 
 
Many of the downstream mechanisms utilized by TGF-β to regulate T cells 
remain unclear. Although we did not observe enhanced TGF-β signaling in Drak2-/- T 
cells via Smad proteins, it was possible that Drak2 regulated the pathway through 
alternative mechanisms. Therefore, we explored the effects of TGF-β on several T cell 
functions in vitro. TGF-β suppresses T cell receptor-induced proliferation of naïve T cells 
in vitro [53]. Thus, we examined if naïve Drak2-/- T cells were more sensitive to TGF-β- 
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Figure 4-1. Smad2 translocation is not enhanced in Drak2-/- T cells compared to 
wildtype T cells. 
 
Wildtype and Drak2-/- CD4+ T cells were purified with magnetic beads and stimulated on 
anti-CD3-coated coverglass slides along with soluble anti-CD28 for 24 hours. Half of the 
cells were treated with TGF-β for the final 20 minutes of culture. Cells were fixed, 
permeabilized, and stained with DAPI (blue), phalloidin (green), and anti-Smad2 (red). 
Images were collected via confocal microscopy. Cells from 2 mice per group were 
pooled. Data are representative of two independent experiments. 
 
Wildtype   
Drak2-/- 
CD3/CD28  
CD3/CD28  
+ TGF-β  
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Figure 4-2. Smad2 and Smad2/3 complex phosphorylation is not enhanced in 
Drak2-/- T cells compared to wildtype T cells. 
 
(A) Wildtype and Drak2-/- splenocytes, and FACS sorted naïve CD4+ and CD8+ T cells 
were stimulated for 2 hours with anti-CD3 and anti-CD28, with or without 2 ng/ml TGF-
β for one additional hour. Cells were lysed and analyzed by western blot with antibodies 
specific for Smad2, phosphorylated Smad2, and HSP90 as a loading control. Cells were 
pooled from 9 wildtype and 8 Drak2-/- mice. Data are representative of two independent 
experiments. (B) Wildtype and Drak2-/- splenocytes were stimulated for 2 hours with 
anti-CD3 and anti-CD28 with or without increasing concentrations of TGF-β for one 
additional hour. The cells were harvested, stained with antibodies specific for CD4, CD8, 
and pSmad2/3, and analyzed by flow cytometry. The average mean fluorescence intensity 
(MFI) of pSmad2/3 expression is shown for 3 mice per group. There was no significant 
difference in the response of the wildtype and Drak2-/- cells according to the Mann-
Whitney U-test. Data are representative of 3 independent experiments.   
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mediated inhibition of proliferation than naive wildtype T cells. Naïve OT-II and         
OT-II.Drak2-/- CD4+ T cells were stimulated with OVA323-pulsed splenocytes in the 
presence or absence of TGF-β, and analyzed for proliferation. The number of live, 
divided CD4+ T cells decreased in response to TGF-β (Figure 4-3A). However, the effect 
of TGF-β inhibition was comparable between OT-II and OT-II.Drak2-/- T cells. We also 
tested the effect of TGF-β on proliferation of naïve CD8+ T cells, by stimulating OT-I and 
OT-I.Drak2-/- T cells with OVA257-pulsed splenocytes in the presence of TGF-β. Similar 
to CD4+ T cells, the number of live, divided CD8+ T cells decreased in response to TGF-
β, and the amount of suppression was similar between OT-I and OT-I.Drak2-/- T cells 
(Figure 4-3B), again suggesting that neither TGF-β signaling nor its downstream effects 
were enhanced in the absence of Drak2. 
 
TGF-β can abrogate survival signals provided by IL-15, but not those elicited by 
IL-2 and IL-7 in expanding CD8+ T cells [54]. To determine if TGF-β function in 
response to opposing cytokines is altered in the absence of Drak2, we explored the 
antagonistic effects of TGF-β on cell recovery and survival of activated CD8+ cells. OT-I 
and OT-I.Drak2-/- cells were stimulated with OVA257-pulsed splenocytes for two days. 
Cells were then washed and cultured with exogenous IL-2, IL-7, or IL-15 with or without 
TGF-β for an additional four days. The addition of TGF-β decreased the number of live 
CD8+ T cells compared to culture in media alone (Figure 4-4A). Adding IL-2, IL-7, and 
IL-15 enhanced the recovery of live CD8+ T cells compared to culture in media alone. 
The addition of TGF-β masked the increased recovery in response to IL-15, but not IL-2 
and IL-7. Decreased cell recovery in response to TGF-β compared to culture in media 
alone correlated with an increase in the proportion of Annexin V+ apoptotic cells   
(Figure 4-4B). The addition of TGF-β abrogated the survival effects of IL-15, but did not 
alter the anti-apoptotic effects of IL-2 and IL-7. However, the ability of TGF-β to oppose 
the effects of IL-15, but not IL-2 and IL-7 was comparable between OT-I and OT-
I.Drak2-/- T cells, suggesting that these TGF-β-mediated effects are not enhanced in the 
absence of Drak2. These data further indicate that TGF-β signaling and function is not 
increased in Drak2-/- T cells compared to wildtype T cells following in vitro stimulation. 
 
 
TGF-β-mediated T cell differentiation is not altered in the absence of Drak2 
 
Another function of TGF-β is the induction of peripheral regulatory T cells [55]. 
As regulatory T cells are critical to prevent autoimmune diseases, we explored if there 
were alterations in TGF-β-mediated differentiation of induced regulatory T cells. Naïve 
wildtype and Drak2-/- CD4+ T cells were purified and stimulated in vitro with anti-CD3, 
anti-CD28, and IL-2, with increasing amounts of TGF-β (Figure 4-5). The addition of 
TGF-β increased Foxp3 expression, indicative of regulatory T cell induction. However, 
we did not observe an enhanced induction in the percent (Figure 4-5A) or number 
(Figure 4-5B) of Foxp3+CD4+ cells in the absence of Drak2. These data also suggest that 
TGF-β functions similarly in wildtype and Drak2-/- T cells that were activated in vitro. 
Therefore, Drak2 may not act as a negative regulator of TGF-β signaling in T cells. 
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Figure 4-3. TGF-β-mediated inhibition of naïve T cell proliferation is comparable 
between wildtype and Drak2-/- T cells. 
 
(A) Naïve OT-II and OT-II.Drak2-/- CD4+ T cells were FACS-sorted and stimulated with 
irradiated splenocytes loaded with 10µM OVA323 peptide in the presence or absence of 
10-fold TGF-β titrations for three days. The number of live, divided Foxp3-CD4+ cells 
are shown for each titration. Cells were obtained from one OT-II or OT-II.Drak2-/- 
mouse and tested in quadruplicate. Data are representative of five separate experiments. 
(B) Naïve OT-I and OT-I.Drak2-/- CD8+ T cells were sorted and stimulated with 
splenocytes loaded with 100pM OVA257 peptide in the presence or absence of 10-fold 
TGF-β titrations. Two days later, cells were harvested and analyzed by flow cytometry. 
The number of live, divided CD8+ cells are shown for each titration. Cells were obtained 
from one OT-I or OT-I.Drak2-/- mouse and tested in quadruplicate. Data are 
representative of three separate experiments. There was no significant difference in the 
response of the wildtype and Drak2-/- cells according to the Mann-Whitney U-test. 
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Figure 4-4. TGF-β-mediated responses to opposing cytokines are comparable 
between wildtype and Drak2-/- T cells. 
 
Naïve OT-I and OT-I.Drak2-/- CD8+ T cells were FACS-sorted and stimulated with 
100nM OVA257–pulsed splenocytes for 2 days. Cells were harvested and replated at equal 
numbers with or without various cytokine combinations. Cytokines were replenished 2 
days later. Cells were harvested and analyzed by flow cytometry on day 6. (A) The 
number of live, CD8+ cells and (B) percent Annexin V+ of CD8+ cells are shown for each 
cytokine condition. Cells were obtained from one OT-I or OT-I.Drak2-/- mouse and tested 
in quadruplicate. Data are representative of two independent experiments. *P < 0.05 
(Mann-Whitney U-test). 
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Figure 4-5. TGF-β-mediated regulatory T cell induction is not altered in the 
absence of Drak2. 
 
Naïve wildtype and Drak2-/- CD4+ T cells were purified and stimulated with 1µg/ml anti-
CD3 and 1µg/ml anti-CD28 with 20ng/ml IL-2 alone or plus 10-fold TGF-β titrations for 
3 days. The (A) percent and (B) number of Foxp3+ cells of electronically gated CD4+ 
cells is shown. There was no significant difference in the response of the wildtype and 
Drak2-/- cells according to the Mann-Whitney U-test.   
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Enhanced susceptibility to death of Drak2-/- T cells compared to wildtype T cells is 
independent of TGF-β signaling in vitro 
 
We previously showed that Drak2-/- T cells exhibit enhanced susceptibility to 
death in vivo, which promotes resistance to T1D and MS [23]. In addition, we found that 
following in vitro stimulation with anti-CD3 and anti-CD28, a greater proportion of 
Drak2-/- T cells were apoptotic compared to wildtype T cells (Figure 4-6A and 4-6B, left 
portion of graph). Although we did not observe differences in TGF-β signaling in the 
absence of Drak2, there may be alternative TGF-β-mediated effects on T cell survival. 
Thus, we sought to determine if the survival defect in Drak2-/- T cells compared to 
wildtype T cells was due to enhanced TGF-β signaling. To test this, we compared T cell 
survival between wildtype and Drak2-/- T cells that exhibit impaired TGF-β signaling due 
to expression of a dominant-negative TGF-β receptor II (DNRII) transgene. The DNRII 
transgene is a kinase-dead mutant that blocks signaling through the endogenous TGF-β 
receptor by competing for TGF-β binding [17]. Naïve CD4+ and CD8+ T cells were 
sorted from wildtype, Drak2-/-, DNRII, and DNRII.Drak2-/- mice. The purified T cells 
were stimulated in vitro with anti-CD3 and anti-CD28. We found that even with the 
severe reduction in TGF-β signaling, there was an increase in the proportion of nonviable 
DNRII.Drak2-/- CD4+ (Figure 4-6A) and CD8+ (Figure 4-6B) T cells compared to DNRII 
CD4+ and CD8+ T cells. These data show that the enhanced death in the Drak2-/- T cells 
following in vitro stimulation is not due to increased TGF-β signaling, and suggest that 
alternative signaling pathways play a role. 
 
 
Discussion 
 
TGF-β is a multifunctional cytokine that controls many aspects of T cell behavior 
and elicits protective effects in several autoimmune diseases [51]. It has been suggested 
that Drak2 functions as a negative regulator of TGF-β signaling [10]. As TGF-β can 
inhibit proliferation, survival, and differentiation of T cells, enhanced TGF-β signaling in 
Drak2-/- T cells could contribute to the resistance to autoimmune disease in the Drak2-/- 
mice via one or more of these mechanisms. However, our data suggest that in primary T 
cells stimulated in vitro, Drak2 does not function as a negative regulator of this pathway. 
Smad2/3 signaling after TGF-β stimulation was not enhanced in Drak2-/- T cells 
compared to wildtype T cells. Importantly, the impact of TGF-β on T cell behavior was 
not enhanced in the absence of Drak2 as evidenced by equal inhibition of naïve T cell 
proliferation, comparable effects on activated CD8+ T cell accumulation and survival, 
and similar induction of regulatory T cells in wildtype and Drak2-/- T cells. 
 
The previous studies that suggested Drak2 negatively regulates TGF-β signaling 
were performed in tumor cell lines [10]. It is possible that Drak2 inhibits TGF-β in 
certain tumor cells, but not in primary T cells. Mutations that lead to tumorigenesis could 
facilitate a role for Drak2 regulation in TGF-β signaling. Thus, as reported in certain 
tumors, Drak2 may function to negatively regulate TGF-β signaling and promote 
tumorigenesis [10]. However, this is contrary to other reports that describe Drak2 as a  
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Figure 4-6. Enhanced susceptibility to death of Drak2-/- T cells compared to 
wildtype T cells is independent of TGF-β signaling in vitro. 
 
Naïve (CD25-CD44lo) T cells were purified from wildtype, Drak2-/-, DNRII, and DNRII. 
Drak2-/- mice and stimulated with anti-CD3 and anti-CD28 for 2–3 days. The percent of 
nonviable (A) CD4+ or (B) CD8+ T cells is shown. Cells were obtained from one mouse 
per group and tested in quadruplicate. Data are representative of four separate 
experiments. **P < 0.01, ***P < 0.001 (Mann-Whitney U-test). 
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tumor suppressor [11,15,30]. Therefore, the role of Drak2 in different types of tumors is  
also controversial and needs to be studied further. Interestingly, we have shown that 
Drak2-/- mice respond similarly to wildtype mice in various in vivo tumor models, again 
suggesting that the role of Drak2 in cell lines may not mimic its role under physiological 
conditions [32].  
 
Another possible explanation for the discrepancy between our results in primary T 
cells and the previous data in tumor cell lines is that during development, the Drak2-/- T 
cells may have compensated for the loss of Drak2 through modifications of alternate 
pathways involved in TGF-β regulation. For example, increased levels of Smad7, a 
negative regulator of TGF-β signaling [56], could mask alterations in TGF-β signaling in 
the absence of Drak2. Therefore, Drak2-/- T cells may exhibit altered signaling pathways 
that function differently compared to physiological conditions in wildtype T cells, which 
warrants further investigation.  Furthermore, it is important to investigate the molecular 
mechanisms of Drak2 in primary T cells, as these are the cells relevant to the induction or 
resistance to autoimmunity. The importance of Drak2 specifically in T cells during 
autoimmunity was highlighted in our previous studies, which demonstrated that the 
resistance to disease in the mouse model of MS was due to Drak2-deficiency in T cells 
[23]. In addition, we found that the resistance to T1D was also due to the absence of 
Drak2 in T cells (Chapter 3). 
 
 Together, our data presented here indicate that TGF-β signaling is not enhanced in 
Drak2-/- T cells following in vitro stimulation. Consequently, Drak2 does not function as 
a negative regulator of TGF-β signaling in T cells, which are critical for the induction of 
autoimmunity. Therefore, further investigation of the potential molecular mechanisms by 
which Drak2 functions during autoimmune disease is required to gain insight into the 
etiology of these diseases. 
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CHAPTER 5.    DRAK2 ALTERS ACTIN POLYMERIZATION AND ACTIN-
DEPENDENT T CELL FUNCTIONS 
 
 
Introduction 
 
Drak2-/- mice are resistant to autoimmune diseases in models of T1D and MS due 
to decreased accumulation of infiltrating T cells in the pancreas and CNS, respectively. 
Decreased accumulation was, at least in part, due to enhanced susceptibility to death of 
Drak2-/- T cells [4,19,23]. Studies in the T1D model showed that while antigen-specific 
NOD.Drak2-/- T cells proliferated in the draining, pancreatic lymph nodes, accumulation 
of these cells decreased as the cells divided. While there was an overall increase in the 
proportion of apoptotic cells in the absence of Drak2, the exact mechanism for enhanced 
death has not been determined, and it is not clear if other factors, such as defective 
proliferation, also mediate decreased accumulation.   
 
Actin is a globular protein that is highly conserved in most eukaryotic cells, where 
it serves many important functions [57]. Specifically, the actin cytoskeleton plays pivotal 
roles in T cell activation, division, adhesion, and migration, which ultimately facilitate 
effective immune responses. T cells lacking key cytoskeletal regulatory proteins 
demonstrate that these deficiencies lead to impaired T cell functions involving F-actin 
reorganization, proliferation and other defects [58], highlighting the importance of 
efficient actin dynamics in T cell biology. Given that proper actin polymerization is 
required for productive T cell proliferation and survival, it is possible that altered actin 
polymerization plays a role in the accumulation defect of Drak2-/- T cells.   
 
Therefore, we investigated whether defects in proliferation and actin dynamics 
contributed to the decreased T cell accumulation observed in the absence of Drak2. We 
found that upon in vitro stimulation, Drak2-/- CD4 T cells exhibit a progressive decrease 
in cell number per division, and decreased overall cell survival. Live cell imaging 
revealed altered cell division of Drak2-/- T cells, which was associated with abnormal 
morphology and defects in cell cycle progression. Drak2-/- T cells also displayed reduced 
actin filament polymerization, migration, and conjugate formation with antigen 
presenting cells (APC). In addition, the activation of an important actin-regulatory 
protein, Rac, was reduced in the absence of Drak2. This finding suggests that Drak2 
mediates actin dynamics either upstream or in collaboration with Rac-GTP in the actin 
polymerization pathway. Taken together, these data provide evidence that Drak2 plays a 
novel role in mediating cytoskeletal rearrangements via direct or indirect mechanisms, 
which may affect optimal T cell survival, proliferation, and other T cell functions to 
ultimately impact autoimmune diseases such as T1D and MS.  
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Results 
 
 
Drak2-/- CD4 T cells exhibit decreased accumulation upon stimulation in vitro 
 
 To test whether decreased accumulation of Drak2-/- CD4+ T cells was due to 
decreased survival, defective proliferation, or a combination of both, we tested whether in 
vitro T cell stimulation would recapitulate the survival defect previously observed in 
Drak2-/- T cells in vivo [19,21,23]. We sorted naïve CD4+ T cells from the spleen and 
peripheral lymph nodes of wildtype and Drak2-/- mice. Purified T cells were labeled with 
the fluorescent dye, CFSE, to track cell division, and stimulated with anti-CD3 and anti-
CD28 for 24 and 48 hours. Cells were harvested and stained with a viability dye. While 
the numbers of viable wildtype and Drak2-/- CD4+ T cells were similar at 24 hours 
following activation, there were significantly fewer viable Drak2-/- T cells by 48 hours 
(Figure 5-1A). Furthermore, a greater proportion of Drak2-/- CD4+ T cells were not 
viable compared to wildtype CD4+ T cells, 24 and 48 hours after stimulation         
(Figure 5-1B). The enhanced cell death in the Drak2-/- CD4+ T cells at 24 hours after 
stimulation likely contributed to the decreased number of viable Drak2-/- CD4+ T cells 
observed at 48 hours compared to wildtpye CD4+ T cells. As the CD4+ T cells have not 
begun to divide at 24 hours after stimulation, yet show increased apoptosis at this time, 
alterations occurring prior to cell division potentially mediate cell survival fates and 
subsequent accumulation. A detailed analysis of the number of cells in each division 72 
hours after stimulation showed that the number of Drak2-/- T cells per division decreased 
significantly as cells proliferated compared to wildtype T cells (Figure 5-1C and 5-1D). 
These results show that the defect in Drak2-/- T cell survival observed in vivo is also 
evident in vitro. Therefore, we will utilize this culture system to study the molecular 
mechanisms by which Drak2 affects T cell accumulation and function. While we also 
found similar trends for Drak2-/- CD8+ T cell survival defects compared to wildtype 
CD8+ T cells (data not shown), Drak2-/- CD4+ T cells displayed a more prominent and 
consistent survival defect than Drak2-/- CD8+ T cells, therefore we will focus our 
investigations primarily on CD4+ T cells.    
 
 
CD4+ T cells display abnormal morphology and alterations during interphase in the 
absence of Drak2 
 
To investigate the dynamics of proliferation, we utilized live cell imaging. We 
purified wildtype and Drak2-/- CD4+ T cells and stimulated them with anti-CD3 and anti-
CD28 in chambered coverglass slides. Images were collected every 6 minutes from 18-36 
hours after stimulation. Time-lapse imaging revealed a higher proportion of activated 
Drak2-/- T cells that had blasted, but not completed cell division by 36 hours in culture, 
compared to wildtype T cells (data not shown). In addition, Drak2-/- T cells exhibited an 
irregular cell morphology, which correlated with the prolonged inability to divide 
(Figure 5-2A). Notably, not all Drak2-/- T cells exhibited abnormal morphology. A 
portion of Drak2-/- T cells divided comparably to wildtype T cells, explaining why there 
is only a partial block in T cell proliferation and accumulation in the absence of Drak2. 
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Figure 5-1. Drak2-/- CD4 T cells exhibit decreased accumulation upon stimulation 
in vitro. 
 
CD4+ T cells were purified from the lymph nodes of wildtype and Drak2-/- mice using 
negative selection with Miltenyi magnetic beads. The cells were stimulated in vitro with 
plate-bound anti-CD3 and soluble anti-CD28 for 24, 48, and 72 hours. After 24 and 48 
hours, cells were harvested and stained with antibodies specific for anti-CD4 and 
viability dye. (A) The number of viable CD4+ cells and (B) the percent of nonviable 
CD4+ cells is shown for each time point, as analyzed by flow cytometry. (C) and (D) 
CD4+ T cells were stained with CFSE, harvested at 72 hours post-stimulation, stained 
with anti-CD4, then analyzed by flow cytometry. (C) The CFSE levels on electronically 
gated viable CD4+ cells are shown. (D) The number of viable CD4+ cells per division, 
based on CFSE histogram analysis, is shown. Samples represent two pooled mice per 
group and were tested in triplicate. Data were analyzed by two-way ANOVA with 
Bonferroni post-tests and error bars represent standard deviation.  Data are representative 
of greater than three independent experiments. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. 
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Figure 5-2. CD4 T cells display abnormal morphology and alterations during 
interphase in the absence of Drak2. 
 
 (A) CD4+ T cells were negatively selected from the lymph nodes of wildtype and  
Drak2-/- mice, then stimulated with anti-CD3 and anti-CD28 in chambered coverglass 
slides for 36 hours. Live cell images were collected every 6 minutes from 18-36 hours 
following stimulation. The images shown were captured approximately 32 hours after 
stimulation. Black arrows indicate Drak2-/- CD4+ T cells exhibiting abnormal 
morphology. Cells were pooled from two mice per group. Data are representative of two 
independent experiments. (B) Naïve wildtype and Drak2-/- CD4+ T cells were FACS 
sorted and stimulated with anti-CD3 and anti-CD28 for 24 hours. Cells were harvested, 
fixed, stained with propidium iodide, and analyzed by flow cytometry. The percent of 
CD4+ cells per cell cycle phase is shown. Cells were pooled from two mice per group. 
Samples were tested in duplicate and error bars represent standard deviation. Data are 
representative of two separate experiments. (C) and (D) Wildtype and Drak2-/- CD4+ T 
cells were negatively selected and stimulated for 48 hours with anti-CD3 and anti-CD28 
in chambered coverglass slides. Cells were fixed, permeabilized, stained with DAPI, and 
images were collected. (C) The representative images show chromosomal dynamics 
during the phases of mitosis. (D) The number of cells per 50 mitotic cells in each phase is 
shown. Cells were pooled from two mice per group. Data represent one experiment.   
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The elongated morphology and prolonged division time observed in the absence 
of Drak2, suggested that there may be defects in completing the cell cycle. Therefore, we 
investigated cell cycle progression utilizing propidium iodide (PI) staining, a DNA 
intercalating agent. Naïve CD4+ T cells were sorted from the lymph nodes and spleen of 
wildtype and Drak2-/- mice, then stimulated in vitro for 24 hours with anti-CD3 and anti-
CD28. There was a greater proportion of Drak2-/- CD4+ T cells in the G1 phase at 24 
hours and a significantly decreased proportion in the G2-M phase, compared to wildtype 
cells (Figure 5-2B). These data suggest that there is a defect or delay in G1-S phase 
transition in the absence of Drak2. Therefore, this interruption in G1-S phase transition 
during interphase of the cell cycle, may contribute to the decreased accumulation 
observed in Drak2-/- T cells following stimulation.  
 
To determine if the Drak2-/- CD4+ T cells that progressed beyond the G1 to S 
phase proceeded through mitosis normally, we stimulated wildtype and Drak2-/- CD4+ T 
cells for 48 hours in chambered coverglass slides. Cells were then stained with DAPI, a 
fluorescent stain that binds DNA, to identify the mitotic phases and to track chromosomal 
segregation. Wildtype and Drak2-/- T cells exhibited similar dynamics in terms of 
chromosomal segregation during mitosis (Figure 5-2C). Furthermore, the number of 
cells per 50 mitotic cells, in each phase of mitosis, at 48 hours after stimulation was 
similar for wildtype and Drak2-/- T cells (Figure 5-2D). These data suggest that there are 
no obvious defects in microtubule function in regards to chromosomal segregation and 
that mitosis is not altered in the absence of Drak2.  Furthermore, these findings imply 
that Drak2-/- cells that exit interphase and enter mitosis successfully complete cell cycle 
and proliferate. Conversely, the subset of Drak2-/- T cells that demonstrate defects in G1 
to S phase transition during interphase, preceding mitosis, exhibit abnormal morphology 
and alterations in cell division, which may halt proliferation of these cells. Interestingly, 
these proliferative defects may render cells more susceptible to apoptosis, which could 
account for both decreased survival and reduced accumulation in the absence of Drak2.  
 
 
Actin polymerization is decreased in Drak2-/- CD4+ T cells compared to wildtpye 
CD4+ T cells 
 
 Abnormal morphology and altered proliferation in the absence of Drak2 suggests 
Drak2 may play a role in actin cytoskeletal processes. Therefore, we next measured actin 
filament polymerization following T cell activation. We purified wildtype and Drak2-/- 
CD4 T cells and stimulated them with anti-CD3 and anti-CD28 for 48 hours in vitro. The 
mean fluorescence intensity of phalloidin, a bicyclic peptide that selectively binds 
polymerized actin (F-actin), was measured in viable CD4 T cells. There was no 
significant difference in basal F-actin expression between wildtype and Drak2-/- T cells 
prior to stimulation. However, 48 hours after stimulation, there was significantly lower F-
actin expression in the absence of Drak2 (Figure 5-3A and 5-3B). This trend was also 
seen at 72 hours (data not shown). These data suggest that Drak2 impacts actin 
polymerization, as the expression of F-actin is significantly reduced in its absence.    
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Figure 5-3. Actin polymerization is decreased in Drak2-/- CD4 T cells compared to 
wildtpye CD4 T cells. 
 
CD4+ T cells were negatively selected from lymph nodes of wildtype and Drak2-/- mice. 
Cells were either left unstimulated or stimulated for 48 hours with plate-bound anti-CD3 
and soluble anti-CD28. Cells were harvested and stained with a viability dye and anti-
CD4, then fixed, permeabilized, stained with phalloidin, and analyzed by flow cytometry. 
(A) Representative histograms of phalloidin mean fluorescence intensity (MFI) on 
electronically gated viable CD4+ T cells. (B) Bar graphs representing MFI expression is 
shown. Samples represent two pooled mice per group and were tested in triplicate. Data 
were analyzed by two-way ANOVA with Bonferroni post-tests and error bars represent 
standard deviation. Data are representative of greater than three independent experiments. 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. (C) Naïve wildtype and Drak2-/- CD4+ T cells were 
FACS sorted and stimulated with anti-CD3 and anti-CD28. RNA was extracted from 
CD4+ T cells at 40 hours post-stimulation. The relative amount of β-actin (Actb) and γ- 
actin (Actg1) mRNA, normalized to GAPDH, was measured utilizing qPCR analysis.  
Three mice per group were tested. Data were analyzed using Mann-Whitney U test (two-
tailed) and error bars represent SEM. Data represent two experiments. (D) Naïve (CD25-
CD44loCD62Lhi) CD4+ T cells were harvested from the spleen and lymph nodes of 
wildtype and Drak2-/- mice. Naïve CD4+ T cells were stimulated for 24 and 48 hours with 
anti-CD3 and anti-CD28, harvested, then stained with viability dye and antibodies 
specific for CD4. Cells were fixed, permeabilized, and stained with DNase I to 
selectively identify G-actin. G-actin MFI was determined by flow cytometry at the 
specified time points. Samples were tested in duplicate or triplicate. Error bars represent 
standard deviation and data are representative of two separate experiments.   
 
 
%
 o
f M
ax
 
Phalloidin 
Wildtype   
Drak2-/- 
Naive Stimulated 
A 
D C 
B 
24 48 
0
500
1000
1500
2000 Wildtype 
Drak2-/- 
Hours post-stimulation
G
-a
ct
in
 M
FI
Actb Actg1
0
1
2
3 Wildtype
Drak2-/-    
R
el
at
iv
e 
m
R
N
A 
qu
an
tit
y
(n
or
m
al
iz
ed
 to
 G
AP
D
H
)
* 
 Naïve                        48 
   Hours post-stimulation 
P
ha
llo
id
in
 M
FI
 
na
ive
 
48
 ho
urs
0
100
200
300
Wildtype  
Drak2-/-    
*
24 48 
0
500
1000
1500
200 Wildtype 
Drak2-/- 
Hours post-stimulation
G
-a
ct
in
 M
FI
 50 
To examine whether the decrease in polymerized actin in Drak2-/- CD4+ T cells 
was due to decreased gene expression and availability of actin subunits, we first 
measured mRNA expression of β-actin (Actb) and γ- actin (Actg1) in CD4+ T cells 
stimulated with anti-CD3 and anti-CD28 for 40 hours.  There were no significant 
differences in levels of β- or γ-actin mRNA between wildtype and Drak2-/- CD4+ T cells 
(Figure 5-3C). These data imply that alterations in actin polymerization are not due to 
reduced expression of the genes required for actin protein expression. Next, we 
determined if the expression of globular actin (G-actin) protein monomers, the building 
blocks for F-actin, was altered in the absence of Drak2. We sorted naïve CD4+ T cells 
from the spleen and lymph nodes of wildtype and Drak2-/- mice. Cells were stimulated 
with anti-CD3 and anti-CD28 for 40 hours in vitro, and G-actin monomer expression was 
measured with fluorescently labeled DNase I, which selectively binds G-actin. G-actin 
expression was similar between wildtype and Drak2-/- CD4 T cells (Figure 5-3D). 
Similar results for actin polymerization studies were also observed in CD8+ T cells (data 
not shown). These data suggest that alterations in polymerized actin are likely due to 
impairments within the actin polymerization pathway, rather than decreased mRNA or 
protein expression and monomer availability in the absence of Drak2. 
 
 
Actin-dependent T cell functions are impaired in the absence of Drak2  
 
To explore actin-dependent T cell functions, we investigated T cell:APC 
conjugation, which is a pivotal step in the initiation of immunological synapse formation 
and T cell activation.  The establishment of actin-dependent protrusions in T cells is 
required for this initial interaction [59]. We sorted naïve CD8+ T cells from OT-I and OT-
I.Drak2-/- mice and cultured them in vitro with splenocytes pulsed with increasing 
amounts of OVA257 peptide, the cognate antigen for OT-I T cells. After 10 minutes, the 
number of T cells forming conjugates with the antigen-pulsed APCs was measured by 
flow cytometry. Significantly fewer conjugates formed between APCs and OT-I.Drak2-/- 
CD8+ T cells compared to OT-I CD8+ T cells (Figure 5-4A). These data suggest that 
Drak2 plays an important role in mediating T cell:APC conjugation, which is likely due 
to a direct or indirect role in actin polymerization.   
 
Cell migration also requires intact actin dynamics. Therefore, we investigated 
whether there were defects in T cell migration in the absence of Drak2. Purified wildtype 
and Drak2-/- T cells were stimulated for 2 hours in vitro with anti-CD3 and anti-CD28. 
The ability of the activated T cells to migrate in response to the chemoattractant, CCL19, 
was tested in a transwell migration assay. The percent of Drak2-/- T cells that migrated in 
response to CCL19 was significantly decreased compared to wildtype T cells         
(Figure 5-4B). These data suggest that Drak2 plays a role in T cell migration. To 
determine if actin polymerization was altered in response to chemokine treatment, we 
cultured unstimulated wildtype and Drak2-/- T cells for 20 minutes in media, then added 
CCL19. Cells were harvested and fixed at various time points and phalloidin binding was 
examined. We found that F-actin expression was decreased in Drak2-/- T cells compared 
to wildtype T cells after treatment with CCL19 (Figure 5-4C). This difference was  
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Figure 5-4. Actin-dependent T cell functions are impaired in the absence of 
Drak2.   
   
(A) Naïve OT-I and OT-I.Drak2-/- CD8+ T cells were FACS sorted and co-cultured with 
CFSE-labeled, OVA257-loaded splenocytes for 10 minutes, then fixed. Cells were stained 
for antibodies specific for B220 and CD8, and analyzed by flow cytometry. The percent 
of total cells that formed conjugates (B220+CD8+) is shown for various OVA257 peptide 
concentrations. Samples represent two pooled mice per group and were tested in 
triplicate.  Data were analyzed by two-way ANOVA with Bonferroni post-tests and error 
bars represent standard deviation.  Data represent one experiment.  (B) Negatively 
selected wildtype and Drak2-/- CD4+ and CD8+ T cells were stimulated for 2 hours with 
anti-CD3 and anti-CD28. T cells were harvested, counted, and equal numbers were 
replated in a 96-transwell plate that held either media only or CCL19 chemokine. The 
percent of T cells that migrated by 2.5 hours into the receiver plate is shown. Samples 
represent three pooled mice per group and were tested in triplicate. Data were analyzed 
by two-way ANOVA with Bonferroni post-tests and error bars represent standard 
deviation. Data are representative of two experiments.  (C) Negatively selected wildtype 
and Drak2-/- CD4+ and CD8+ T cells were rested at 37°C for 20 minutes.  T cells were left 
untreated or treated with CCL19 for various time points, fixed, then stained with 
antibodies specific for CD4 and CD8.  T cells were then permeabilized and stained with 
phalloidin. The MFI of F- phalloidin for CD4 and CD8 T cells at each time point is 
shown.  Samples represent two pooled mice per group.  Data represent one experiment.        
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observed as early as 10-20 seconds after CCL19 treatment. These data demonstrate that 
Drak2 modifies actin  polymerization in response to chemoattractants, as well as TCR 
stimulation, and the absence of Drak2 impairs actin-mediated T cell functions.  
  
 
Active Rac-GTP expression is decreased in Drak2-/- T cells upon stimulation 
 
The activation of Rho GTPases, a family of proteins involved in the regulation of 
the actin cytoskeleton, is critical for several T cell functions, including activation, 
proliferation, and migration [58,60]. Interestingly, G1 to S phase transition during the cell 
cycle is also mediated by Rho GTPase proteins [57]. Therefore, we investigated the 
expression of active Rac, a member of the Rho GTPase family. T cells were purified 
from the lymph nodes of wildtype and Drak2-/- mice and stimulated in vitro for short 
periods of time by incubating the cells with biotin-conjugated anti-CD3 and anti-CD28 
antibodies, followed by streptavidin crosslinking. Rac is active when bound to GTP, 
while GDP-bound Rac is inactive. Therefore, we measured the amount of active Rac by 
flow cytometry using an antibody that specifically binds to Rac-GTP. Following 
stimulation, Rac-GTP levels were significantly diminished in Drak2-/- CD4 and CD8 T 
cells compared to wildtype T cells (Figure 5-5A and 5-5B). Levels of Rac-GTP 
decreased in wildtype T cells after 2 minutes, but remained lower at all time points in 
Drak2-/- T cells. These data suggest that Drak2 directly or indirectly modifies the actin 
polymerization pathway either in collaboration with or upstream of Rac.   
 
 
Discussion 
 
Drak2-/- mice are resistant to T cell-mediated autoimmune diseases due to 
decreased accumulation of T cells in the target organ [23]. Previous studies showed that 
this decreased accumulation is due, at least in part, to enhanced death in Drak2-/- T cells 
following stimulation [19,23]. However, as T cell accumulation is a culmination of both 
survival and productive proliferation, Drak2 may also influence T cell proliferation. The 
data presented here show that defective proliferation does in fact, contribute to the 
decreased T cell accumulation observed in the absence of Drak2. We show that, 
following stimulation, Drak2-/- T cells exhibited abnormal morphology, reduced actin 
polymerization, and a block in the G1-S phase transition during cell cycle. Furthermore, 
actin-dependent T cell functions including APC:T cell conjugation and migration were 
decreased in the absence of Drak2. Interestingly, similar to Drak2-/- T cells, T cells that 
are deficient in molecules involved in actin dynamics, such as Vav1 and WASP, also 
exhibit impaired T cell proliferation and migration [58], further implicating a direct or 
indirect role for Drak2 in actin polymerization. Finally, we show decreased levels of Rac-
GTP, the active form of Rac, which is downstream of Vav1, in the absence of Drak2. 
Together these data suggest that Drak2 impacts actin polymerization upstream of Rac 
(Figure 5-6). Defects in cell cycle progression and proliferation may render Drak2-/- T 
cells more susceptible to death. Thus, reduced survival and accumulation of Drak2-/- T 
cells may be mediated by these faulty actin dynamics.  
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Figure 5-5. Active Rac-GTP expression is decreased in Drak2-/- T cells upon 
stimulation. 
 
Wildtype and Drak2-/- CD4+ and CD8+ T cells were negatively selected and stimulated in 
vitro for the specified periods of time with biotin-conjugated anti-CD3 and anti-CD28 
antibodies followed by streptavidin crosslinking. T cells were stained with anti-CD4 and 
anti-CD8, then fixed, permeabilized and stained with an anti-Rac-GTP antibody. The 
MFI of the Rac-GTP antibody in (A) CD4+ and (B) CD8+ T cells at each time point 
relative to the Rac-GTP antibody MFI in unstimulated wildtype or Drak2-/- T cells is 
shown.  Samples represent two pooled mice per group.  Data represent one experiment.        
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Figure 5-6. Proposed model of Drak2 function in actin polymerization. 
 
Drak2 promotes actin polymerization, either directly or indirectly, upstream of Rac. 
Following TCR stimulation and activation of LCK, ZAP70, and LAT, Drak2 may 
function as a scaffold protein along with LAT and SLP76 for actin-regulatory proteins 
including VAV1, or may mediate activation of these proteins. The regulatory effects of 
Drak2 lead to enhanced actin polymerization and actin-mediated functions. 
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The direct or indirect role of Drak2 in actin signaling may also account for many 
of the previously described phenotypes of Drak2-/- T cells. For example, Drak2-/- T cells 
are hyperproliferative to suboptimal TCR stimulation [2]. Productive TCR signaling 
requires an intact actin cytoskeleton to form a stable immunological synapse. The 
cytoskeletal components are also required to regulate the location of negative regulators 
of TCR signaling and to dissolve the synapse to prevent excessive signaling [59]. Thus, 
defects in actin polymerization could cause aberrant localization of key negative 
regulators or prolonged synapse formation, which would increase T cell activation and 
subsequent proliferation. For example, PKC-θ localization to the synapse, which is 
dependent on F-actin, has been shown to negatively regulate the stability of T cell 
synapses [61]. Therefore, if actin dynamics are decreased in the absence of Drak2, 
localization of PKC-θ to the synapse may also be decreased, which would lead to more 
stable synapse formation and enhanced signaling. The finding that there were fewer 
APC:T cell conjugates in the absence of Drak2 suggests that Drak2 may impact synapse 
formation and activation, although the role of Drak2 in actin-mediated immunological 
synapse formation requires further elucidation. 
 
In addition, Drak2 is a negative regulator of T cell activation, and Drak2-/- T cells 
exhibit increased calcium flux, augmented cytokine production, and enhanced IL-2 
signaling, compared to wildtype T cells [4–6]. Several reports suggest an 
interdependence between calcium signaling and actin rearrangements; however, the 
factors that link these two processes remain elusive [62]. Inhibition of actin 
polymerization with cytochalasin B and latrunculin B led to elevated intracellular Ca2+ 
levels and increased cytokine production in T cells [63]. Thus, it is possible that 
decreased actin polymerization in Drak2-/- T cells mediates the increased calcium flux 
and increased IL-2 and IL-4 production observed in these cells after activation. While 
Drak2 has been shown to interact with several proteins involved in calcium signaling, 
including CHP, PKC-γ, and PKD, these interactions were not confirmed in primary T 
cells. Therefore, the exact mechanism by which Drak2 regulates calcium signaling in T 
cells is unclear. Thus, it is possible that decreased actin polymerization alters T cell 
activation in the absence of Drak2, which may contribute to augmented calcium 
signaling.  
 
In addition to enhanced susceptibility to death and defects in proliferation, the 
reduced accumulation of Drak2-/- T cells in the target organs during autoimmune disease 
could also be due to deficiencies in migration. Studies showed that wildtype and Drak2-/- 
T cells exhibited similar expression levels of the adhesion molecules and chemokine 
receptors required for entry into the CNS [23], however it was not clear whether these 
receptors functioned similarly in the absence of Drak2. Furthermore, although the 
migration of T cells into nonlymphoid organs during delayed-type hypersensitivity, 
LCMV infection, and mouse hepatitis virus (MHV) was not altered in the absence of 
Drak2 [23,25], the mechanisms that mediate migration of T cells into non-lymphoid 
organs may vary between infection and autoimmunity. We showed that T cell migration 
in response to CCL19, a chemoattractant that is also expressed in the CNS, was decreased 
in the absence of Drak2. Therefore, decreased migration efficiency in the absence of 
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Drak2 may also contribute to decreased accumulation in target organs during T1D and 
MS.  
 
Together, the data presented here offer important insight into a novel role for 
Drak2 in actin polymerization via direct or indirect mechanisms. Further investigations to 
determine the expression and/or activation of additional actin proteins should be explored 
to determine more specifically if Drak2 functions directly within the actin polymerization 
pathway or if indirect effects mediate alterations observed in the absence of Drak2. We 
highlighted several previously described characteristics of Drak2-/- T cells that could be 
caused by defects in actin polymerization. This leads to an intriguing hypothesis that 
Drak2 modifies the actin pathway to mediate its downstream effects on T cell activation, 
proliferation, accumulation, cytokine production, migration, and possibly calcium 
signaling. Furthermore, perhaps these slight alterations in various processes synergize to 
lead to autoimmune disease resistance in the absence of Drak2. Whether Drak2 plays 
distinct roles in each of these pathways, or if there is interplay between these roles, 
wherein one factor precedes and mediates the others, remains to be determined.  
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CHAPTER 6.    DISCUSSION AND CONCLUSIONS 
 
 
Discussion 
 
Drak2 plays a key role in the induction of T1D and MS by promoting the 
accumulation of T cells after stimulation [23]. Consequently, Drak2-/- mice are resistant 
to disease in models of MS and T1D. Yet, Drak2-/- mice respond comparably to wildtype 
mice in several models of infection. In fact, the response is enhanced in the absence of 
Drak2 following infection with some pathogens [24–26] and (unpublished data). 
Furthermore, Drak2 does not function as a tumor suppressor or an oncogene in various in 
vivo tumor models [32]. Based on these findings, Drak2 is an ideal target to inhibit for the 
treatment of T cell-mediated autoimmune diseases. While several studies show that 
Drak2 contributes to T1D and MS, the exact mechanism(s) by which Drak2 mediates 
autoimmunity is not clear. Therefore, the investigations performed in this dissertation 
aimed to examine and clarify more precise mechanisms by which Drak2 influences 
autoimmunity.  
 
While it was established that Drak2 expression within the T cells during MS 
mediates disease resistance, the mechanism for resistance to T1D is less clear. One study 
showed that enhanced susceptibility to death within the T cells led to decreased T cell 
accumulation in the pancreas and the draining lymph nodes, and thus, disease resistance 
[23]. However, an alternative study suggested that T1D was mediated by Drak2 
expression in the β-islet cells within the pancreas, which caused increased apoptosis and 
destruction of those cells [14]. Therefore, we investigated whether Drak2 expression in 
the T cells, β-islet cells, or a combination of both, contributes to T1D. Utilizing the NOD 
mouse model, we determined that resistance to T1D is due to the absence of Drak2 in the 
T cells, rather than the β-islet cells.  This is evident because the resistance to T1D in 
NOD.Drak2-/- mice transferred with the T cells and was independent of Drak2 expression 
in islet cells. Importantly, enhanced T cell death was not the sole mediator of resistance, 
as regulatory T cells were also required to elicit T1D resistance in the absence of Drak2. 
Further studies showed an enhanced proportion of Treg cells in Drak2-/- mice compared 
to wildtype mice, and enhanced IL-2 signaling within Drak2-/- thymocytes, compared to 
wildtype thymocytes. We further observed that enhanced IL-2 signaling and increased 
Stat5 phosphorylation mediated the increased proportion of Foxp3-epxressing Tregs in 
the absence of Drak2. These data suggest that the increase in Drak2-/- Tregs, along with 
an increased susceptibility to death within Drak2-/- T cells both cooperate to prevent T1D. 
Furthermore, the enhanced expression of pStat5 in the absence of Drak2 suggests that 
Drak2 functions as a negative regulator of IL-2 signaling upstream of Stat5 activation. 
The exact mechanism by which Drak2 decreases pStat5-mediated Foxp3 induction 
warrants further exploration. In addition to mediating enhanced Foxp3 induction in 
Drak2-/- thymocytes, enhanced IL-2 signaling may also contribute to increased apoptosis 
or other downstream functional effects in mature, peripheral T cells that could contribute 
to autoimmune disease resistance in the absence of Drak2. These options should also be 
investigated.  
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As T cells play pivotal roles in eliciting resistance to MS and T1D in the absence 
of Drak2, it is important to study the molecular mechanisms of Drak2 in primary T cells 
to further understand how Drak2 mediates autoimmunity. Therefore, we further explored 
T cell functions that could mediate this resistance. A recent investigation, utilizing 
several tumor cell lines, suggested that Drak2 is a negative regulator of TGF-β signaling 
[10]. TGF-β elicits many effects on T cells that could suppress autoimmunity, including 
inhibition of proliferation, survival, and differentiation. If Drak2 were a negative 
regulator of TGF-β signaling, then these processes should be enhanced in the absence of 
Drak2 and could mediate resistance to autoimmune diseases. However, T cells were not 
specifically investigated in the previous study. Therefore, we investigated if Drak2 
functioned as a negative regulator of TGF-β signaling in T cells. Our data show that 
Drak2 does not function as a negative regulator of this pathway in primary T cells. We 
did not observe enhanced Smad2/3 signaling after TGF-β stimulation in Drak2-/- T cells 
compared to wildtype T cells. Furthermore, several TGF-β-mediated functional effects 
were similar between wildtype and Drak2-/- T cells, including inhibition of naïve T cell 
proliferation, T cell accumulation and survival, and Treg induction. While Drak2 may 
serve as a negative regulator in tumor cell lines, possibly due to pathway alterations that 
may occur in response to mutations that lead to tumorigenesis, we contend that Drak2 
does not function as a negative regulator of TGF-β signaling in primary T cells. 
Furthermore, alterations in TGF-β signaling do not mediate susceptibility to autoimmune 
disease in the absence of Drak2. Therefore, we continued our study to determine 
alternative molecular mechanism(s) by which Drak2 functions to promote autoimmune 
disease within T cells. 
 
Decreased T cell accumulation in target organs during MS and T1D mediates 
disease resistance in the absence of Drak2 [23]. T cell accumulation is a result of efficient 
survival and proliferation. Although decreased survival of Drak2-/- T cells following 
stimulation has been shown to mediate, at least in part, this decreased accumulation 
[19,23], detailed investigations to study proliferation had not been performed. Therefore, 
we investigated if there were proliferative alterations in the absence of Drak2. We found 
that defective proliferation, in addition to decreased survival, contributed to the decreased 
T cell accumulation observed in the absence of Drak2 in vitro. We also showed that 
following stimulation, Drak2-/- T cells exhibited abnormal morphology, altered cell 
proliferation, and a delay or block in G1-S phase transition during cell cycle. In addition, 
we observed decreases in actin polymerization, and actin-dependent T cell functions, 
including migration and APC:T cell conjugation, in the absence of Drak2. Therefore, we 
hypothesize that Drak2 modifies the actin polymerization pathway either directly or 
indirectly. Furthermore, the Rho family of GTPases have been shown to mediate G1 to S 
phase transition during the cell cycle. Interestingly, we observed decreased active Rac-
GTP, a member of the Rho Family, in the absence of Drak2, suggesting that Drak2 
impacts the actin polymerization pathway upstream of Rac activation. Rac activation via 
VAV1 is pivotal for the accumulation of F-actin at the immunological synapse, T cell 
activation, lamellipod formation, and other important actin-mediated functions [64]. 
Generally, the actin polymerization pathway and its associated proteins also mediate 
numerous other T cell functions, including cell cycle progression, proliferation, 
migration, and calcium dynamics. These data suggest that Drak2 contributes to T cell-
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mediated autoimmune diseases via its effects on actin polymerization by influencing 
small alterations within these processes.  
 
Taken together, these findings suggest novel roles for Drak2 in IL-2 signaling and 
actin polymerization, either directly or indirectly. Interestingly, increased IL-2-mediated 
functions including enhanced Treg induction and augmented IL-2 mediated activation-
induced T cell death, along with alterations in actin-mediated T cell functions, including 
altered immunological synapse formation, defective proliferation, and reduced migration 
could all potentially mediate disease resistance and decreased T cell accumulation in the 
pancreas and CNS during T1D and MS, respectively. Therefore, in the absence of Drak2, 
small alterations within these processes could collectively contribute to autoimmune 
disease. Interestingly, defects in actin polymerization also contribute to enhanced calcium 
signaling and increased cytokine signaling and production.  Thus, our future studies will 
further elucidate whether Drak2 plays distinct roles within each pathway, or if it plays a 
direct role in actin polymerization to mediate calcium and IL-2 signaling.  
 
 
Future Studies  
 
 
Drak2 and IL-2 signaling 
 
 We showed that Drak2 negatively regulated IL-2 signaling in CD4 SP thymocytes 
and thus, reduced the development of Tregs. Enhanced phosphorylation of Stat5 in the 
absence of Drak2 suggests that Drak2 blocks signaling upstream of Stat5 activation. 
There are several regulatory mechanisms by which Drak2 could elicit this effect. 
Therefore, future studies will focus on identifying the exact mechanism by which Drak2 
reduces IL-2 signaling. Drak2 may act as a scaffold protein to recruit other negative 
regulators, including SOCS1, SOCS3, or SHP-1, to the receptor complex or may mediate 
the activation of these proteins. Alternatively, Drak2 may function at the IL-2 receptor to 
dampen IL-2 signaling by blocking recruitment or activation of Jak1 or Jak3. Thus, 
studies to examine the levels of activated Jak1 and Jak3, which are downstream of the IL-
2 receptor, but upstream of Stat5 activation, will determine if Drak2 mediates negative 
regulatory effects at the receptor complex, or if its effects are elicited downstream of Jak 
activation. To further explore potential interactions and scaffold functions of Drak2, we 
will perform co-immunoprecipitation assays to identify possible Drak2 interactions with 
IL-2 signaling molecules, as well as the known negative regulators of the pathway. 
Interestingly, mass spectrometry data suggested that Drak2 interacts with Stat5a 
(unpublished data). Therefore, Stat5 will be the initial protein of interest.   
 
 Further studies will be conducted to determine if IL-2 signaling is enhanced in 
mature, peripheral T cells. Although previous data showed that Drak2-/- T cells produce 
more IL-2 than wildtype T cells, detailed analysis of IL-2 signaling has not been 
investigated in peripheral T cells. In addition, we will test if functions downstream of IL-
2 are altered in the absence of Drak2. Specifically, enhanced IL-2 signaling has been 
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shown to enhance apoptosis in mature T cells [48]. Therefore, we will determine the 
effects of exogenous IL-2 treatment on Drak2-/- T cell survival.  
 
 
Drak2 and actin polymerization 
 
 Our data show that Drak2 contributes to actin polymerization via direct or indirect 
mechanisms, and its absence leads to multiple defects in actin-mediated T cell functions. 
Notably, APC:T cell conjugation was decreased in the absence of Drak2, which has 
implications for altered immunological synapse dynamics and activation. Therefore, 
future studies will utilize lipid bilayers and fluorescent microscopy to explore 
immunological synapse formation and actin localization at the immunological synapse. 
These studies will allow us to determine if alterations in actin polymerization in the 
absence of Drak2 lead to either hyperstable or unstable synapses.  
 
 In addition, we determined that Drak2 likely functions upstream of Rac1 
activation. Future studies will explore the expression, activation, and localization of actin 
proteins upstream of Rac-GTP in the actin polymerization pathway. Because several of 
the proteins upstream of Rac activation also possess scaffold functions, we will also 
perform co-immunoprecipitation assays to determine if Drak2 functions in the actin 
polymerization pathway via potential interactions with these proteins of interest, 
including LAT, SLP76, and VAV1.  
 
 
Conclusions 
 
It is important to investigate and determine potential molecular mechanisms by 
which Drak2 functions during autoimmunity to better understand the etiology of 
autoimmune diseases, as well as to validate the use of Drak2 as a target for therapeutic 
treatment of these diseases. Our investigations to determine the role of Drak2 in 
autoimmunity have revealed several novel findings for Drak2 in T cell function. First, we 
determined that Drak2 expression in T cells contributes to autoimmune disease in T1D, 
similar to what was previously shown for MS. Furthermore, enhanced death of these T 
cells was not the sole mediator for resistance, as Tregs were required. In addition, an 
enhanced proportion of Tregs in the absence of Drak2 was observed, which may also 
contribute to T1D resistance. The increase in Tregs was mediated by enhanced IL-2 
signaling during Treg development in the thymus, and not due to enhanced TGF-β 
mediated Treg induction in the periphery. In fact, TGF-β signaling is not enhanced in the 
absence of Drak2, and TGF-β functions are comparable to wildtype T cells. These data 
dispute the suggestion that Drak2 is a negative regulator of TGF-β signaling, at least in 
primary T cells. Surprisingly, Drak2 also modifies actin polymerization, either directly or 
indirectly, upstream of Rac1 to elicit alterations in several T cell functions, including 
survival, proliferation, migration, and APC:T cell conjugation. Taken together, these 
findings offer an intriguing concept, in which slight modifications within several 
processes may collaborate and contribute to autoimmune disease resistance in the 
absence of Drak2. We are hopeful that these findings will benefit future studies to 
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develop novel therapeutic treatments for autoimmune diseases. Furthermore, the fact that 
Drak2-/- mice respond effectively to infectious pathogens and tumors highlights that the 
aforementioned modifications do not collaborate to mediate detrimental effects during 
productive immune responses, supporting the notion that slight modifications in certain 
pathways may be more detrimental for T cell responses during autoimmunity rather than 
during immunity to foreign agents and tumors. Most importantly, Drak2 remains a viable 
target to inhibit for therapeutic treatment during T-cell mediated autoimmune diseases. 
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